PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2442153-1	1987	Novobiocin and coumermycin, inhibitors of the B subunit of Escherichia coli DNA gyrase, inhibit the binding of Xenopus transcription factor IIIA (TFIIIA) to the 5 S RNA gene.	Novobiocin	0-10	general transcription factor 3A L homeolog	Xenopus laevis	146-152
2610497-6	1989	Strain CDC-1, prototype of heterogeneous methicillin-resistant S. aureus, contained penicillin-binding protein (PBP) 2a; its DNA could transform a methicillin-susceptible and novobiocin-resistant recipient to methicillin resistance with ca.	Novobiocin	175-185	AT695_RS11765	Staphylococcus aureus	84-110
2610497-6	1989	Strain CDC-1, prototype of heterogeneous methicillin-resistant S. aureus, contained penicillin-binding protein (PBP) 2a; its DNA could transform a methicillin-susceptible and novobiocin-resistant recipient to methicillin resistance with ca.	Novobiocin	175-185	AT695_RS11765	Staphylococcus aureus	112-115
3141117-1	1988	Of 7 plasmids we tested, the plasmid pORF2 was eliminated in vitro with the most efficiency by treatment with subinhibitory concentrations of novobiocin, coumermycin and 10 quinolones.	Novobiocin	142-152	L1 element, subfamily A, member 101	Mus musculus	37-42
2840567-3	1988	The topoisomerase II inhibitor, novobiocin, at concentrations in the range of 35-140 microM, effectively blocked the ability of Ca2+ to increase PRL mRNA levels.	Novobiocin	32-42	prolactin	Rattus norvegicus	145-148
2840567-4	1988	Examination of the effects of novobiocin on the levels of protein synthesis, glucose-regulated protein (GRP) 78 mRNA, histone 3 mRNA, and 18S ribosomal RNA indicated that the drug selectivity inhibited PRL gene expression.	Novobiocin	30-40	prolactin	Rattus norvegicus	202-205
2536684-3	1989	All transformants examined produced normal amounts of the low-affinity penicillin-binding protein (PBP) 2a, and methicillin resistance and the capacity to produce PBP 2a showed the same degree of genetic linkage to the novobiocin resistance marker with both homogeneous and heterogeneous DNA donors.	Novobiocin	219-229	AT695_RS11765	Staphylococcus aureus	99-102
2536684-3	1989	All transformants examined produced normal amounts of the low-affinity penicillin-binding protein (PBP) 2a, and methicillin resistance and the capacity to produce PBP 2a showed the same degree of genetic linkage to the novobiocin resistance marker with both homogeneous and heterogeneous DNA donors.	Novobiocin	219-229	AT695_RS11765	Staphylococcus aureus	163-166
2843181-0	1988	Fibroblast-like transformation and c-myc gene alteration of human hepatocytes induced by novobiocin and butyrate.	Novobiocin	89-99	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	35-40
2843181-4	1988	Therefore, it is suggested that chemical modulation of nuclear proteins by novobiocin and butyrate may be responsible, at least partly, for the alteration of the chromatin structure of c-myc gene and the fibroblast-like transformation of Chang liver cells.	Novobiocin	75-85	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	185-190
2832958-6	1988	The stimulation of DNA repair synthesis in thymus cells caused by novobiocin with the aid of DNA polymerase beta could be compensated by hyperthermia.	Novobiocin	66-76	activation-induced cytidine deaminase	Rattus norvegicus	86-89
2832958-6	1988	The stimulation of DNA repair synthesis in thymus cells caused by novobiocin with the aid of DNA polymerase beta could be compensated by hyperthermia.	Novobiocin	66-76	DNA polymerase beta	Rattus norvegicus	93-112
2825970-4	1988	Novobiocin (an inhibitor of topoisomerase II) markedly antagonized the enhancing effect of estrogen on VP-16-induced DNA cleavage, while neutral nucleoid sedimentation detected less than 10% of such strand breaks revealed in estrogen-treated cells by alkaline unwinding.	Novobiocin	0-10	host cell factor C1	Homo sapiens	103-108
2823231-0	1987	Novobiocin inhibits initiation of RNA polymerase II-directed transcription of the mouse metallothionein-I gene independent of its effect on DNA topoisomerase II.	Novobiocin	0-10	metallothionein 1	Mus musculus	88-105
2823231-1	1987	The requirement for ATP hydrolysis in the initiation of RNA polymerase II (Pol II)-directed transcription and the relationship between ATP and novobiocin action led us to investigate whether novobiocin could inhibit transcription of the mouse metallothionein-I (MT-I) gene.	Novobiocin	191-201	metallothionein 1	Mus musculus	243-260
2823231-1	1987	The requirement for ATP hydrolysis in the initiation of RNA polymerase II (Pol II)-directed transcription and the relationship between ATP and novobiocin action led us to investigate whether novobiocin could inhibit transcription of the mouse metallothionein-I (MT-I) gene.	Novobiocin	191-201	metallothionein 1	Mus musculus	262-266
2823231-2	1987	Novobiocin inhibited the MT-I gene transcription in a fractionated rat hepatoma nuclear extract in a dose-dependent manner by direct interaction with a nuclear factor(s).	Novobiocin	0-10	metallothionein 1	Rattus norvegicus	25-29
2823231-4	1987	Preincubation of the nuclear extract with ATP prevented the action of novobiocin on MT-I gene transcription.	Novobiocin	70-80	metallothionein 1	Mus musculus	84-88
2442153-3	1987	Novobiocin and coumermycin inhibit TFIIIA-dependent DNA renaturation.	Novobiocin	0-10	general transcription factor 3A L homeolog	Xenopus laevis	35-41
2442153-4	1987	Novobiocin dissociates TFIIIA.5 S RNA gene complexes and TFIIIA.5 S RNA complexes (7 S particles).	Novobiocin	0-10	general transcription factor 3A L homeolog	Xenopus laevis	23-29
2442153-4	1987	Novobiocin dissociates TFIIIA.5 S RNA gene complexes and TFIIIA.5 S RNA complexes (7 S particles).	Novobiocin	0-10	general transcription factor 3A L homeolog	Xenopus laevis	57-63
2442153-5	1987	Novobiocin induces TFIIIA aggregation, a phenomenon likely to be responsible for the inhibition of TFIIIA-DNA interactions.	Novobiocin	0-10	general transcription factor 3A L homeolog	Xenopus laevis	19-25
2442153-5	1987	Novobiocin induces TFIIIA aggregation, a phenomenon likely to be responsible for the inhibition of TFIIIA-DNA interactions.	Novobiocin	0-10	general transcription factor 3A L homeolog	Xenopus laevis	99-105
2442153-6	1987	Novobiocin inhibition of TFIIIA can be reversed by dilution.	Novobiocin	0-10	general transcription factor 3A L homeolog	Xenopus laevis	25-31
3606995-8	1987	Lower processivity was induced by lowering the reaction temperature, by adding spermine, spermidine, or putrescine, in the presence of the antibiotics novobiocin and ciprofloxacin, by adding Escherichia coli single-stranded DNA binding protein, or by adding calf thymus topoisomerase II and RNase H. Three single-stranded DNA binding proteins from calf thymus, including unwinding protein 1, do not affect processivity to any significant extent.	Novobiocin	151-161	heterogeneous nuclear ribonucleoprotein A1	Bos taurus	371-390
3588299-0	1987	Novobiocin interferes with the binding of transcription factors TFIIIA and TFIIIC to the promoters of class III genes.	Novobiocin	0-10	general transcription factor IIIA	Homo sapiens	64-70
3588299-0	1987	Novobiocin interferes with the binding of transcription factors TFIIIA and TFIIIC to the promoters of class III genes.	Novobiocin	0-10	general transcription factor IIIC subunit 1	Homo sapiens	75-81
3588299-3	1987	Using DNase I footprinting, we show here that novobiocin inhibits the specific binding of polymerase III transcription factors TFIIIA and TFIIIC to the promoters of the 5S RNA and VA RNA genes, respectively.	Novobiocin	46-56	general transcription factor IIIA	Homo sapiens	127-133
3588299-3	1987	Using DNase I footprinting, we show here that novobiocin inhibits the specific binding of polymerase III transcription factors TFIIIA and TFIIIC to the promoters of the 5S RNA and VA RNA genes, respectively.	Novobiocin	46-56	general transcription factor IIIC subunit 1	Homo sapiens	138-144
3528175-0	1986	Selective increase of c-myc mRNA levels by methylglyoxal-bis (guanylhydrazone) and novobiocin in serum-stimulated fibroblasts.	Novobiocin	83-93	myc proto-oncogene protein	Mesocricetus auratus	22-27
2432161-2	1986	Inhibitors of both gyrase subunits, nalidixic acid and novobiocin, affect the expression of cysB, as monitored by beta-galactosidase activity in cysB::lac fusion strains.	Novobiocin	55-65	galactosidase beta 1	Homo sapiens	114-132
4083857-3	1985	Disintegration of the cells of the novobiocin resistant staphylococci resulted in a higher yield of the membrane protein, the membrane fraction being characterized by a activity of phospholipase A.	Novobiocin	35-45	phospholipase A and acyltransferase 1	Homo sapiens	181-196
3733712-1	1986	When the topoisomerase II inhibitor, novobiocin, is administered to embryonic chicken red blood cells, it induces the in vivo release of an endogenous nuclease which cleaves specifically within internucleosomal spacer DNA and within nuclease-hypersensitive sites in the active chromatin of intact cells.	Novobiocin	37-47	DNA cross-link repair 1C	Gallus gallus	151-159
3733712-1	1986	When the topoisomerase II inhibitor, novobiocin, is administered to embryonic chicken red blood cells, it induces the in vivo release of an endogenous nuclease which cleaves specifically within internucleosomal spacer DNA and within nuclease-hypersensitive sites in the active chromatin of intact cells.	Novobiocin	37-47	DNA cross-link repair 1C	Gallus gallus	233-241
3733712-2	1986	This in vivo released nuclease activity is induced by novobiocin only in metabolically active immature red blood cells.	Novobiocin	54-64	DNA cross-link repair 1C	Gallus gallus	22-30
3733712-4	1986	Although novobiocin is required to induce release and/or activation of the nuclease, the activity of the nuclease, once activated, is independent of novobiocin.	Novobiocin	9-19	DNA cross-link repair 1C	Gallus gallus	75-83
2992834-9	1985	Furthermore, the suppression of induced strand break accumulation is partly due to a suppression by novobiocin of the uptake and phosphorylation of cytosine arabinoside; breaks accumulated in u.v.-irradiated cells in the presence of aphidicolin, an inhibitor of DNA polymerase alpha that does not require phosphorylation, are less novobiocin-sensitive.	Novobiocin	100-110	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	262-282
6408486-5	1983	Hydroxyurea, novobiocin and aphidicolin, inhibitors of ribonucleotide reductase, topoisomerase and DNA polymerase alpha, respectively, all inhibit thymidylate synthase in intact S phase CHEF/18 cells, but not in their soluble extracts.	Novobiocin	13-23	thymidylate synthase	Cricetulus griseus	147-167
2989538-1	1985	In the studies reported here we show that the antibiotic novobiocin, an in vitro inhibitor of topoisomerase II, blocks the Drosophila heat shock response.	Novobiocin	57-67	Topoisomerase 2	Drosophila melanogaster	94-110
227861-3	1979	Coumermycin, novobiocin, nalidixic acid, and oxolinic acid are known to be inhibitors of Escherichia coli gyrase, to inhibit E. coli DNA replication, to abolish colicin E1 replication, and to depress the supercoiling of phage lambda DNA, the last two via inhibition of the DNA gyrase.	Novobiocin	13-23	DNA topoisomerase II alpha	Homo sapiens	273-283
6206865-0	1983	The in vitro inhibition of DNA polymerase alpha and avian reverse transcriptase by novobiocin.	Novobiocin	83-93	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	27-47
6206865-1	1983	Novobiocin inhibits animal DNA polymerase alpha and avian reverse transcriptase activities when these enzymes are assayed in vitro with activated DNA as template.	Novobiocin	0-10	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	27-47
6206865-3	1983	DNA polymerase alpha and reverse transcriptase are inhibited by different mechanisms: in the case of the retroviral enzyme the effect of novobiocin is not overcome by dilution of the drug, while in the case of polymerase alpha the inhibition disappeared after novobiocin dilution.	Novobiocin	137-147	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	0-20
6206865-3	1983	DNA polymerase alpha and reverse transcriptase are inhibited by different mechanisms: in the case of the retroviral enzyme the effect of novobiocin is not overcome by dilution of the drug, while in the case of polymerase alpha the inhibition disappeared after novobiocin dilution.	Novobiocin	260-270	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	0-20
6841589-0	1983	Rapid determination of novobiocin resistance of coagulase-negative staphylococci with the MS-2 system.	Novobiocin	23-33	MS2	Homo sapiens	90-94
6841589-2	1983	The MS-2 system correctly classified 91.5% of 82 isolates as either susceptible or resistant to novobiocin in an average time of 5.8 h.	Novobiocin	96-106	MS2	Homo sapiens	4-8
6253912-1	1980	The DNA gyrase inhibitor novobiocin specifically inhibits the transcription of ribosomal RNA in vivo while protein synthesis and the mRNA transcription are only partly affected.	Novobiocin	25-35	DNA topoisomerase II alpha	Homo sapiens	4-14
11894947-2	1983	Using both cores and DNA-protein complexes as templates, it was also demonstrated that novobiocin, an inhibitor of DNA gyrase, inhibited in vitro DNA replication by preventing formation of the initiation complex.	Novobiocin	87-97	DNA topoisomerase II alpha	Homo sapiens	115-125
6269086-6	1981	The gyrB protein ATPase activity is competitively inhibited by novobiocin and related coumarin antibiotics.	Novobiocin	63-73	ATPase	Escherichia coli	17-23
32791353-6	2020	Further, SPR experiments revealed strong in-vitro binding of telmisartan and novobiocin to nsP2 protein.	Novobiocin	77-87	sepiapterin reductase	Homo sapiens	9-12
5276074-0	1971	Function of teichoic acids and effect of novobiocin on control of Mg2+ at the bacterial membrane.	Novobiocin	41-51	mucin 7, secreted	Homo sapiens	66-69
226966-1	1979	We have used the antibiotics coumermycin A1, novobiocin, and oxolinic acid, which are specific inhibitors of DNA gyrase, to study the coupled transcription and translation of several bacterial and plasmid genes in a DNA-directed cell-free system.	Novobiocin	45-55	DNA topoisomerase II alpha	Homo sapiens	109-119
956057-0	1976	The C-13 NMR spectrum of novobiocin.	Novobiocin	25-35	homeobox C13	Homo sapiens	4-8
32328609-7	2020	The protein expression levels of TFEB, LC3 and P62 were down-regulated significantly by either STA9090 or Novobiocin, under both normoxic and hypoxic conditions.	Novobiocin	106-116	transcription factor EB	Homo sapiens	33-37
32832020-3	2020	Novobiocin, a well characterized DNA gyrase B inhibitor, was identified as the first Hsp90 C-terminal inhibitor that manifested anticancer effects without induction of the HSR.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	85-90
32269321-0	2020	Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.	Novobiocin	140-150	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	35-42
32269321-0	2020	Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.	Novobiocin	140-150	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	98-105
32328609-7	2020	The protein expression levels of TFEB, LC3 and P62 were down-regulated significantly by either STA9090 or Novobiocin, under both normoxic and hypoxic conditions.	Novobiocin	106-116	nucleoporin 62	Homo sapiens	47-50
32328609-10	2020	Whereas both STA9090 and Novobiocin inhibited Hsp90 to bind to the TFEB proximal promoter region, and decreased the activity of TFEB promoter.	Novobiocin	25-35	heat shock protein 90 alpha family class A member 1	Homo sapiens	46-51
32328609-10	2020	Whereas both STA9090 and Novobiocin inhibited Hsp90 to bind to the TFEB proximal promoter region, and decreased the activity of TFEB promoter.	Novobiocin	25-35	transcription factor EB	Homo sapiens	67-71
32328609-10	2020	Whereas both STA9090 and Novobiocin inhibited Hsp90 to bind to the TFEB proximal promoter region, and decreased the activity of TFEB promoter.	Novobiocin	25-35	transcription factor EB	Homo sapiens	128-132
30857829-7	2019	These inhibitory effects of PEN-A were similar to those of novobiocin, an inhibitor binding to interaction site for ATP of C-terminus of Hsp90.	Novobiocin	59-69	heat shock protein 90 alpha family class A member 1	Homo sapiens	137-142
31015586-5	2019	However, MK-571 (MRP inhibitor) and novobiocin (BCRP inhibitor) substantially increased the rate of ALDH-positive CT26 cells based on either Aldefluor or AldeRed588 assays.	Novobiocin	36-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
31015586-5	2019	However, MK-571 (MRP inhibitor) and novobiocin (BCRP inhibitor) substantially increased the rate of ALDH-positive CT26 cells based on either Aldefluor or AldeRed588 assays.	Novobiocin	36-46	aldehyde dehydrogenase family 3, subfamily A1	Mus musculus	100-104
30429362-8	2018	In addition, the mono-ADP-ribosylation inhibitors vitamin K1 and novobiocin inhibited oligomerization of TRIM72, the mechanism by which TRIM72 is recruited to the site of injury.	Novobiocin	65-75	tripartite motif-containing 72	Mus musculus	105-111
30792306-0	2019	Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32.	Novobiocin	77-87	heat shock protein 90 alpha family class A member 1	Homo sapiens	15-36
30792306-4	2019	Here, using biochemical and cell-based assays along with isothermal titration calorimetry, we investigate KU-32, a derivative of the Hsp90 inhibitor novobiocin (NB), for its ability to modulate Hsp90 chaperone function.	Novobiocin	149-159	heat shock protein 90 alpha family class A member 1	Homo sapiens	133-138
30792306-4	2019	Here, using biochemical and cell-based assays along with isothermal titration calorimetry, we investigate KU-32, a derivative of the Hsp90 inhibitor novobiocin (NB), for its ability to modulate Hsp90 chaperone function.	Novobiocin	149-159	heat shock protein 90 alpha family class A member 1	Homo sapiens	194-199
30792306-4	2019	Here, using biochemical and cell-based assays along with isothermal titration calorimetry, we investigate KU-32, a derivative of the Hsp90 inhibitor novobiocin (NB), for its ability to modulate Hsp90 chaperone function.	Novobiocin	161-163	heat shock protein 90 alpha family class A member 1	Homo sapiens	194-199
30792306-5	2019	Although NB and KU-32 differ only slightly in structure, we found that upon binding, they induce completely opposite conformational changes in Hsp90.	Novobiocin	9-11	heat shock protein 90 alpha family class A member 1	Homo sapiens	143-148
30792306-6	2019	We observed that NB and KU-32 both bind to the C-terminal domain of Hsp90, but surprisingly, KU-32 stimulated the chaperone functions of Hsp90 via allosteric modulation of its N-terminal domain, responsible for the chaperone"s ATPase activity.	Novobiocin	17-19	heat shock protein 90 alpha family class A member 1	Homo sapiens	68-73
30792306-6	2019	We observed that NB and KU-32 both bind to the C-terminal domain of Hsp90, but surprisingly, KU-32 stimulated the chaperone functions of Hsp90 via allosteric modulation of its N-terminal domain, responsible for the chaperone"s ATPase activity.	Novobiocin	17-19	heat shock protein 90 alpha family class A member 1	Homo sapiens	137-142
30792306-6	2019	We observed that NB and KU-32 both bind to the C-terminal domain of Hsp90, but surprisingly, KU-32 stimulated the chaperone functions of Hsp90 via allosteric modulation of its N-terminal domain, responsible for the chaperone"s ATPase activity.	Novobiocin	17-19	dynein axonemal heavy chain 8	Homo sapiens	227-233
30015413-8	2019	Bclaf1 interacts with the C-terminal domain of Hsp90alpha, and this interaction is disrupted by the C-terminal domain inhibitor, novobiocin (NB), resulting in proteasome-dependent degradation of Bclaf1.	Novobiocin	129-139	BCL2 associated transcription factor 1	Homo sapiens	0-6
30015413-8	2019	Bclaf1 interacts with the C-terminal domain of Hsp90alpha, and this interaction is disrupted by the C-terminal domain inhibitor, novobiocin (NB), resulting in proteasome-dependent degradation of Bclaf1.	Novobiocin	129-139	heat shock protein 90 alpha family class A member 1	Homo sapiens	47-57
30015413-8	2019	Bclaf1 interacts with the C-terminal domain of Hsp90alpha, and this interaction is disrupted by the C-terminal domain inhibitor, novobiocin (NB), resulting in proteasome-dependent degradation of Bclaf1.	Novobiocin	129-139	BCL2 associated transcription factor 1	Homo sapiens	195-201
30015413-8	2019	Bclaf1 interacts with the C-terminal domain of Hsp90alpha, and this interaction is disrupted by the C-terminal domain inhibitor, novobiocin (NB), resulting in proteasome-dependent degradation of Bclaf1.	Novobiocin	141-143	BCL2 associated transcription factor 1	Homo sapiens	0-6
30015413-8	2019	Bclaf1 interacts with the C-terminal domain of Hsp90alpha, and this interaction is disrupted by the C-terminal domain inhibitor, novobiocin (NB), resulting in proteasome-dependent degradation of Bclaf1.	Novobiocin	141-143	heat shock protein 90 alpha family class A member 1	Homo sapiens	47-57
30015413-8	2019	Bclaf1 interacts with the C-terminal domain of Hsp90alpha, and this interaction is disrupted by the C-terminal domain inhibitor, novobiocin (NB), resulting in proteasome-dependent degradation of Bclaf1.	Novobiocin	141-143	BCL2 associated transcription factor 1	Homo sapiens	195-201
30015413-9	2019	Moreover, NB-induced disruption of Hsp90alpha-Bclaf1 interaction dampened the production of mature c-MYC mRNA and attenuated tumor cell growth in vitro and in vivo.	Novobiocin	10-12	heat shock protein 90 alpha family class A member 1	Homo sapiens	35-45
30015413-9	2019	Moreover, NB-induced disruption of Hsp90alpha-Bclaf1 interaction dampened the production of mature c-MYC mRNA and attenuated tumor cell growth in vitro and in vivo.	Novobiocin	10-12	BCL2 associated transcription factor 1	Homo sapiens	46-52
30015413-9	2019	Moreover, NB-induced disruption of Hsp90alpha-Bclaf1 interaction dampened the production of mature c-MYC mRNA and attenuated tumor cell growth in vitro and in vivo.	Novobiocin	10-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104
30429362-8	2018	In addition, the mono-ADP-ribosylation inhibitors vitamin K1 and novobiocin inhibited oligomerization of TRIM72, the mechanism by which TRIM72 is recruited to the site of injury.	Novobiocin	65-75	tripartite motif-containing 72	Mus musculus	136-142
29759728-1	2018	KU-596 is a second-generation C-terminal heat shock protein 90 KDa (Hsp90) modulator based on the natural product, novobiocin.	Novobiocin	115-125	heat shock protein 90 alpha family class B member 1	Homo sapiens	41-66
30224681-3	2018	Here we show the efficacy and biological mechanism of a Hsp90 inhibitor NCT-50, a novobiocin-deguelin analog hybridizing the pharmacophores of these known Hsp90 inhibitors.	Novobiocin	82-92	heat shock protein 90 alpha family class A member 1	Homo sapiens	56-61
30224681-3	2018	Here we show the efficacy and biological mechanism of a Hsp90 inhibitor NCT-50, a novobiocin-deguelin analog hybridizing the pharmacophores of these known Hsp90 inhibitors.	Novobiocin	82-92	heat shock protein 90 alpha family class A member 1	Homo sapiens	155-160
30374305-0	2018	Novobiocin, a Newly Found TRPV1 Inhibitor, Attenuates the Expression of TRPV1 in Rat Intestine and Intestinal Epithelial Cell Line IEC-6.	Novobiocin	0-10	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	26-31
30374305-0	2018	Novobiocin, a Newly Found TRPV1 Inhibitor, Attenuates the Expression of TRPV1 in Rat Intestine and Intestinal Epithelial Cell Line IEC-6.	Novobiocin	0-10	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	72-77
29759728-1	2018	KU-596 is a second-generation C-terminal heat shock protein 90 KDa (Hsp90) modulator based on the natural product, novobiocin.	Novobiocin	115-125	heat shock protein 90 alpha family class B member 1	Homo sapiens	68-73
30151087-2	2018	After the identification of novobiocin as a C-Hsp90 interacting ligand a diverse gamut of novologues emerged, from which KU-32 and KU-596 exhibited strong neuroprotective activity.	Novobiocin	28-38	heat shock protein 90 alpha family class A member 1	Homo sapiens	44-51
30061663-0	2018	LRP1 is required for novobiocin-mediated fibronectin turnover.	Novobiocin	21-31	LDL receptor related protein 1	Homo sapiens	0-4
29720349-2	2018	Novobiocin, the first Hsp90 C-terminal inhibitor identified, contains a synthetically complex noviose sugar that has limited the generation of structure-activity relationships for this region of the molecule.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	22-27
30061663-0	2018	LRP1 is required for novobiocin-mediated fibronectin turnover.	Novobiocin	21-31	fibronectin 1	Homo sapiens	41-52
30061663-2	2018	We have previously demonstrated that FN interacts directly with Hsp90, as well as showing that the Hsp90 inhibitor novobiocin results in FN turnover via a receptor mediated process.	Novobiocin	115-125	fibronectin 1	Homo sapiens	37-39
30061663-2	2018	We have previously demonstrated that FN interacts directly with Hsp90, as well as showing that the Hsp90 inhibitor novobiocin results in FN turnover via a receptor mediated process.	Novobiocin	115-125	heat shock protein 90 alpha family class A member 1	Homo sapiens	99-104
30061663-5	2018	FN, LRP1 and Hsp90 could be isolated in a common complex, and inhibition of Hsp90 by novobiocin increased the colocalisation of FN and LRP1.	Novobiocin	85-95	fibronectin 1	Homo sapiens	0-2
30061663-5	2018	FN, LRP1 and Hsp90 could be isolated in a common complex, and inhibition of Hsp90 by novobiocin increased the colocalisation of FN and LRP1.	Novobiocin	85-95	heat shock protein 90 alpha family class A member 1	Homo sapiens	76-81
30061663-5	2018	FN, LRP1 and Hsp90 could be isolated in a common complex, and inhibition of Hsp90 by novobiocin increased the colocalisation of FN and LRP1.	Novobiocin	85-95	fibronectin 1	Homo sapiens	128-130
30061663-5	2018	FN, LRP1 and Hsp90 could be isolated in a common complex, and inhibition of Hsp90 by novobiocin increased the colocalisation of FN and LRP1.	Novobiocin	85-95	LDL receptor related protein 1	Homo sapiens	135-139
30061663-6	2018	Novobiocin induced an increase (at low concentrations) followed by a loss of FN that was primarily derived from extracellular matrix-associated FN and led to a concomitant increase in intracellular FN.	Novobiocin	0-10	fibronectin 1	Homo sapiens	77-79
30061663-6	2018	Novobiocin induced an increase (at low concentrations) followed by a loss of FN that was primarily derived from extracellular matrix-associated FN and led to a concomitant increase in intracellular FN.	Novobiocin	0-10	fibronectin 1	Homo sapiens	144-146
30061663-6	2018	Novobiocin induced an increase (at low concentrations) followed by a loss of FN that was primarily derived from extracellular matrix-associated FN and led to a concomitant increase in intracellular FN.	Novobiocin	0-10	fibronectin 1	Homo sapiens	144-146
30061663-7	2018	The effect of novobiocin was specific to LRP1-expressing cells and could be recapitulated by an LRP1 blocking antibody and the allosteric C-terminal Hsp90 inhibitor SM253, but not the N-terminal inhibitor geldanamycin.	Novobiocin	14-24	LDL receptor related protein 1	Homo sapiens	41-45
30061663-7	2018	The effect of novobiocin was specific to LRP1-expressing cells and could be recapitulated by an LRP1 blocking antibody and the allosteric C-terminal Hsp90 inhibitor SM253, but not the N-terminal inhibitor geldanamycin.	Novobiocin	14-24	LDL receptor related protein 1	Homo sapiens	96-100
30061663-7	2018	The effect of novobiocin was specific to LRP1-expressing cells and could be recapitulated by an LRP1 blocking antibody and the allosteric C-terminal Hsp90 inhibitor SM253, but not the N-terminal inhibitor geldanamycin.	Novobiocin	14-24	heat shock protein 90 alpha family class A member 1	Homo sapiens	149-154
30061663-8	2018	Together these data suggest that LRP1 is required for FN turnover in response to Hsp90 inhibition by novobiocin, which may have unintended physiological consequences in contexts where C-terminal Hsp90 inhibition is to be used therapeutically.	Novobiocin	101-111	LDL receptor related protein 1	Homo sapiens	33-37
30061663-8	2018	Together these data suggest that LRP1 is required for FN turnover in response to Hsp90 inhibition by novobiocin, which may have unintended physiological consequences in contexts where C-terminal Hsp90 inhibition is to be used therapeutically.	Novobiocin	101-111	heat shock protein 90 alpha family class A member 1	Homo sapiens	81-86
29677383-3	2018	Here we report on the effect of the most prominent drug candidates, namely, radicicol, geldanamycin, derivatives of purine, and novobiocin, on Hsp90"s characteristic conformational dynamics and the binding of three interaction partners.	Novobiocin	128-138	heat shock protein 90 alpha family class A member 1	Homo sapiens	143-148
29137866-2	2018	Neuroprotective Hsp90 C-terminal inhibitors derived from novobiocin (novologues) include KU-32 and KU-596.	Novobiocin	57-67	heat shock protein 90 alpha family class A member 1	Homo sapiens	16-21
29746111-4	2018	Polymyxin has been shown to synergize with many antibiotics including novobiocin, which inhibits DNA gyrase, by facilitating transport of these antibiotics across the outer membrane.	Novobiocin	70-80	DNA topoisomerase II alpha	Homo sapiens	97-107
29746111-5	2018	Recently, we have shown that novobiocin not only inhibits DNA gyrase but also binds and stimulates LptB, the ATPase that powers LPS transport.	Novobiocin	29-39	DNA topoisomerase II alpha	Homo sapiens	58-68
29746111-10	2018	We also report other novobiocin analogs that inhibit DNA gyrase better than or equal to novobiocin, but bind better to LptB and therefore have even greater LptB stimulatory activity.	Novobiocin	21-31	DNA topoisomerase II alpha	Homo sapiens	53-63
29483524-5	2018	The treatment of specific inhibitors novobiocin (Nov; HSP90) and pifithrin/2-phenylethynesulfonamide (Pif; HSP70) in in-vitro cultured ovules resulted in a fewer number of fiber initials and retardation in fiber elongation.	Novobiocin	37-47	heat shock cognate protein 80-like	Gossypium hirsutum	54-59
29120605-2	2018	Using cell culture models, we previously identified KU-32 as a novobiocin-based C-terminal heat shock protein 90 (Hsp90) inhibitor that decreased c-jun expression and the extent of demyelination.	Novobiocin	63-73	heat shock protein, 3	Mus musculus	91-112
29120605-2	2018	Using cell culture models, we previously identified KU-32 as a novobiocin-based C-terminal heat shock protein 90 (Hsp90) inhibitor that decreased c-jun expression and the extent of demyelination.	Novobiocin	63-73	heat shock protein, 3	Mus musculus	114-119
29120605-2	2018	Using cell culture models, we previously identified KU-32 as a novobiocin-based C-terminal heat shock protein 90 (Hsp90) inhibitor that decreased c-jun expression and the extent of demyelination.	Novobiocin	63-73	jun proto-oncogene	Mus musculus	146-151
30175776-5	2018	Such suppressive effects were maximal at 6 h after heat shock and remained up to 12 h. Interestingly, such effects of heat shock were abrogated by specific inhibitors of HSP90 such as 17-allylamino-17-demethoxygeldanamycin (17-AAG) and novobiocin.	Novobiocin	236-246	heat shock protein, 2	Mus musculus	170-175
28468311-9	2017	Novobiocin, an Hsp90 inhibitor, diminished the NS5 protein amount and virus replication in JEV-infected cells.	Novobiocin	0-10	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	47-50
29247221-3	2017	Where inhibition of Hsp90 with a C-terminal inhibitor, novobiocin, reduced the fibronectin matrix, treatment with an N-terminal inhibitor, geldanamycin, increased fibronectin levels.	Novobiocin	55-65	heat shock protein 90 alpha family class A member 1	Homo sapiens	20-25
29247221-3	2017	Where inhibition of Hsp90 with a C-terminal inhibitor, novobiocin, reduced the fibronectin matrix, treatment with an N-terminal inhibitor, geldanamycin, increased fibronectin levels.	Novobiocin	55-65	fibronectin 1	Homo sapiens	79-90
29028527-1	2017	In order to discover novel Hsp90 inhibitors targeting the C-terminal ATP binding pocket, a novobiocin derivative based ROCS model was constructed for virtual screening.	Novobiocin	91-101	heat shock protein 90 alpha family class A member 1	Homo sapiens	27-32
28940589-2	2017	Novobiocin, a coumarin antibiotic, was the first Hsp90 C-terminal inhibitor identified, however, it manifested poor anti-proliferative activity (SKBr3, IC50  700 mum).	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	49-54
27815129-9	2017	Furthermore, the results proved synergism among essential oils and both antibiotics ofloxacin and novobiocin against the Extended-Spectrum Beta-Lactamase producing E. coli (ESBL).	Novobiocin	98-108	EsbL	Escherichia coli	173-177
28019639-1	2017	BACKGROUND: The aminocoumarin antibiotic, novobiocin, is a natural product that inhibits DNA gyrase, a bacterial enzyme involved in cell division.	Novobiocin	42-52	DNA topoisomerase II alpha	Homo sapiens	89-99
27914946-2	2017	Novobiocin, a coumarin antibiotic, was the first natural product identified that targeted the Hsp90 C-terminal domain and manifested anti-proliferative activity (SKBr3 IC50~700muM).	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	94-99
28123630-7	2017	SMYD3 inhibitors (e.g., BCI-121 and novobiocin) could hopefully fight against tumors with efficacy.	Novobiocin	36-46	SET and MYND domain containing 3	Homo sapiens	0-5
28019639-2	2017	METHOD: More recently, novobiocin was found to act also on eukaryotic cells by blocking the 90 kDa heat shock protein (Hsp90).	Novobiocin	23-33	heat shock protein 90 alpha family class A member 1	Homo sapiens	119-124
28019639-4	2017	As opposed to the geldanamycin and radicicol, the known inhibitors of Hsp90 that bind to the N-terminal region, the binding domain of novobiocin is localized in the C-terminal part of this protein.	Novobiocin	134-144	heat shock protein 90 alpha family class A member 1	Homo sapiens	70-75
27205876-10	2016	Moreover, leptin-induced JAK2/STAT3 phosphorylation was markedly attenuated by the HSP90 inhibitors geldanamycin, radicicol and novobiocin.	Novobiocin	128-138	leptin	Homo sapiens	10-16
27153346-3	2016	Novobiocin, an aminocoumarin antibiotic, was reported to inhibit Hsp90 targeting C-terminal domain, and showed anti-proliferative properties, leading to the development of new and more active compounds.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	65-70
27205876-10	2016	Moreover, leptin-induced JAK2/STAT3 phosphorylation was markedly attenuated by the HSP90 inhibitors geldanamycin, radicicol and novobiocin.	Novobiocin	128-138	Janus kinase 2	Homo sapiens	25-29
27205876-10	2016	Moreover, leptin-induced JAK2/STAT3 phosphorylation was markedly attenuated by the HSP90 inhibitors geldanamycin, radicicol and novobiocin.	Novobiocin	128-138	signal transducer and activator of transcription 3	Homo sapiens	30-35
27205876-10	2016	Moreover, leptin-induced JAK2/STAT3 phosphorylation was markedly attenuated by the HSP90 inhibitors geldanamycin, radicicol and novobiocin.	Novobiocin	128-138	heat shock protein 90 alpha family class A member 1	Homo sapiens	83-88
27037933-0	2016	Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.	Novobiocin	39-49	heat shock protein 90 alpha family class A member 1	Homo sapiens	68-73
27563408-1	2016	Novobiocin is a natural product that binds the Hsp90 C-terminus and manifests Hsp90 inhibitory activity.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	47-52
27563408-1	2016	Novobiocin is a natural product that binds the Hsp90 C-terminus and manifests Hsp90 inhibitory activity.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	78-83
25699150-0	2015	Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors.	Novobiocin	65-75	heat shock protein 90 alpha family class A member 1	Homo sapiens	89-94
26721724-1	2016	6BrCaQ is a promising anti-cancer agent derived from novobiocin, which has been shown to inhibit Hsp90.	Novobiocin	53-63	heat shock protein 90 alpha family class A member 1	Homo sapiens	97-102
26745854-2	2016	The first Hsp90 C-terminus inhibitor, novobiocin, manifested a relatively high IC50 value of ~700 muM.	Novobiocin	38-48	heat shock protein 90 alpha family class A member 1	Homo sapiens	10-15
26916001-6	2016	Novobiocin derivatives, which do not bind the chaperone"s N-terminal ATPase pocket, have emerged over the past decade as an alternative strategy to inhibit Hsp90, but to date, no derivative has been investigated in the clinical setting.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	156-161
26819668-1	2016	KU-32 and KU-596 are novobiocin-derived, C-terminal heat shock protein 90 (Hsp90) modulators that induce Hsp70 levels and manifest neuroprotective activity.	Novobiocin	21-31	heat shock protein 90 alpha family class A member 1	Homo sapiens	52-73
26819668-1	2016	KU-32 and KU-596 are novobiocin-derived, C-terminal heat shock protein 90 (Hsp90) modulators that induce Hsp70 levels and manifest neuroprotective activity.	Novobiocin	21-31	heat shock protein 90 alpha family class A member 1	Homo sapiens	75-80
26819668-1	2016	KU-32 and KU-596 are novobiocin-derived, C-terminal heat shock protein 90 (Hsp90) modulators that induce Hsp70 levels and manifest neuroprotective activity.	Novobiocin	21-31	heat shock protein family A (Hsp70) member 4	Homo sapiens	105-110
26391399-7	2015	Additional Hsp90 inhibitors, including 17-(allylamino)-17-demethoxygeldanamycin, celastrol, and novobiocin also suppressed PMA-induced H1R gene up-regulation.	Novobiocin	96-106	heat shock protein 90 alpha family class A member 1	Homo sapiens	11-16
26391399-7	2015	Additional Hsp90 inhibitors, including 17-(allylamino)-17-demethoxygeldanamycin, celastrol, and novobiocin also suppressed PMA-induced H1R gene up-regulation.	Novobiocin	96-106	histamine receptor H1	Homo sapiens	135-138
25576192-0	2015	Novobiocin and peptide analogs of alpha-factor are positive allosteric modulators of the yeast G protein-coupled receptor Ste2p.	Novobiocin	0-10	alpha-factor pheromone receptor STE2	Saccharomyces cerevisiae S288C	122-127
25576192-7	2015	Immunoblots probing for the Ste2p-[Bio-DOPA]11-mer complex revealed that novobiocin markedly decreased cross-linking of the [Bio-DOPA]11-mer to the receptor, but cross-linking of the alpha-factor analog [Bio-DOPA]13-mer, which interacts with the orthosteric binding site of the receptor, was minimally altered.	Novobiocin	73-83	alpha-factor pheromone receptor STE2	Saccharomyces cerevisiae S288C	28-33
25604133-11	2015	Consistent with HSP90 inhibitory activity, EGCG, novobiocin, and 17-AAG induced changes in HSP90-client proteins in NT cells and larger differences in metastatic cells.	Novobiocin	49-59	heat shock protein 90 alpha family class A member 1	Homo sapiens	16-21
25604133-11	2015	Consistent with HSP90 inhibitory activity, EGCG, novobiocin, and 17-AAG induced changes in HSP90-client proteins in NT cells and larger differences in metastatic cells.	Novobiocin	49-59	heat shock protein 90 alpha family class A member 1	Homo sapiens	91-96
25402753-9	2015	Our results show that disruption of Hsp90alpha/Aha1 interactions with novobiocin-based Hsp90 C-terminal inhibitors may limit the metastatic potential of tumors.	Novobiocin	70-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	36-46
25402753-9	2015	Our results show that disruption of Hsp90alpha/Aha1 interactions with novobiocin-based Hsp90 C-terminal inhibitors may limit the metastatic potential of tumors.	Novobiocin	70-80	activator of HSP90 ATPase activity 1	Homo sapiens	47-51
25402753-9	2015	Our results show that disruption of Hsp90alpha/Aha1 interactions with novobiocin-based Hsp90 C-terminal inhibitors may limit the metastatic potential of tumors.	Novobiocin	70-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	36-41
25742791-3	2015	HDN-1 bound directly to C-terminus of Hsp90alpha, resulting in a potential conformational change that interfered with the binding of 17-AAG and novobiocin to Hsp90alpha.	Novobiocin	144-154	heat shock protein 90 alpha family class A member 1	Homo sapiens	38-48
25742791-3	2015	HDN-1 bound directly to C-terminus of Hsp90alpha, resulting in a potential conformational change that interfered with the binding of 17-AAG and novobiocin to Hsp90alpha.	Novobiocin	144-154	heat shock protein 90 alpha family class A member 1	Homo sapiens	158-168
25462258-2	2015	Current drug discovery efforts toward Hsp90 C-terminal inhibition focus on novobiocin, an antibiotic that was transformed into an Hsp90 inhibitor.	Novobiocin	75-85	heat shock protein 90 alpha family class A member 1	Homo sapiens	38-43
25462258-2	2015	Current drug discovery efforts toward Hsp90 C-terminal inhibition focus on novobiocin, an antibiotic that was transformed into an Hsp90 inhibitor.	Novobiocin	75-85	heat shock protein 90 alpha family class A member 1	Homo sapiens	130-135
25462258-3	2015	Based on structural information obtained during the development of novobiocin derivatives and molecular docking studies, scaffolds containing a biphenyl moiety in lieu of the coumarin ring present in novobiocin were identified as new Hsp90 C-terminal inhibitors.	Novobiocin	67-77	heat shock protein 90 alpha family class A member 1	Homo sapiens	234-239
25462258-3	2015	Based on structural information obtained during the development of novobiocin derivatives and molecular docking studies, scaffolds containing a biphenyl moiety in lieu of the coumarin ring present in novobiocin were identified as new Hsp90 C-terminal inhibitors.	Novobiocin	200-210	heat shock protein 90 alpha family class A member 1	Homo sapiens	234-239
25699150-2	2015	Novobiocin was the first natural product identified as an Hsp90 C-terminal inhibitor; however, it manifests poor antiproliferative activity.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	58-63
24461493-0	2014	Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.	Novobiocin	64-74	heat shock protein 90 alpha family class A member 1	Homo sapiens	78-83
24992077-0	2014	Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.	Novobiocin	44-54	heat shock protein 90 alpha family class A member 1	Homo sapiens	78-83
24785461-4	2014	Till date, a variety of drugs have been identified as Hsp90alpha inhibitors, which include Novobiocin, Clorobiocin, Epigallocatechingallate (EGCG) and Derrubone.	Novobiocin	91-101	heat shock protein 90 alpha family class A member 1	Homo sapiens	54-64
24785461-13	2014	Furthermore, docking studies were performed of various Hsp90alpha inhibitors like Novobiocin, Clorobiocin, Epigallocatechingallate (EGCG) and Derrubone with the previously recognized ATP binding residues of CTD i.e. Leu 665, Leu 666 and Leu 694.	Novobiocin	82-92	heat shock protein 90 alpha family class A member 1	Homo sapiens	55-65
24552830-4	2014	Using multiple preclinical mouse models of inflammatory bowel diseases, we demonstrate a potent anti-inflammatory effect of selective inhibition of the HSP90 C-terminal ATPase using the compound novobiocin.	Novobiocin	195-205	heat shock protein, 3	Mus musculus	152-157
24646925-3	2014	Here, by using the pharmacological Hsp90 inhibitor novobiocin (NB), we investigated the role of Hsp90 and the heat shock response in LPS-induced delayed renal preconditioning.	Novobiocin	51-61	heat shock protein 86, pseudogene 1	Mus musculus	35-40
24646925-13	2014	CONCLUSION: LPS-induced heat shock protein induction and tolerance to a subsequent lethal LPS treatment was prevented by the Hsp90 inhibitor, novobiocin.	Novobiocin	142-152	heat shock protein 86, pseudogene 1	Mus musculus	125-130
24887242-1	2014	BACKGROUND: Novobiocin is a coumarin antibiotic, which affects also eukaryotic cells inhibiting activity of Heat shock protein 90 (Hsp90).	Novobiocin	12-22	heat shock protein 90 alpha family class A member 1	Homo sapiens	108-129
24887242-1	2014	BACKGROUND: Novobiocin is a coumarin antibiotic, which affects also eukaryotic cells inhibiting activity of Heat shock protein 90 (Hsp90).	Novobiocin	12-22	heat shock protein 90 alpha family class A member 1	Homo sapiens	131-136
24461493-2	2014	In an effort to develop more efficacious compounds for Hsp90 inhibition, novobiocin analogues were prepared by replacing the central coumarin core with naphthalene, quinolinone, and quinoline surrogates.	Novobiocin	73-83	heat shock protein 90 alpha family class A member 1	Homo sapiens	55-60
23859777-0	2013	Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.	Novobiocin	39-49	heat shock protein 90 alpha family class A member 1	Homo sapiens	73-94
24552830-4	2014	Using multiple preclinical mouse models of inflammatory bowel diseases, we demonstrate a potent anti-inflammatory effect of selective inhibition of the HSP90 C-terminal ATPase using the compound novobiocin.	Novobiocin	195-205	dynein, axonemal, heavy chain 8	Mus musculus	169-175
24552830-5	2014	Novobiocin-attenuated dextran sulfate sodium-induced colitis and CD45RB adoptive-transfer colitis through the suppression of inflammatory cytokine secretion, including TNF-alpha.	Novobiocin	0-10	tumor necrosis factor	Mus musculus	168-177
24552830-6	2014	In vitro assays demonstrate that CD4 T cells treated with novobiocin produced significantly less TNF-alpha measured by intracellular cytokine staining and by enzyme-linked immunosorbent assay.	Novobiocin	58-68	CD4 antigen	Mus musculus	33-36
24552830-6	2014	In vitro assays demonstrate that CD4 T cells treated with novobiocin produced significantly less TNF-alpha measured by intracellular cytokine staining and by enzyme-linked immunosorbent assay.	Novobiocin	58-68	tumor necrosis factor	Mus musculus	97-106
24552830-11	2014	HSP90 inhibition with novobiocin offers a novel method of inflammatory cytokine suppression without potential for the development of tolerance that limits current antibody-based methods.	Novobiocin	22-32	heat shock protein, 3	Mus musculus	0-5
24643001-7	2014	RESULTS: A 48 hours exposure to novobiocin (500 microM) was followed by a significant increase of [Ca(2+)]i, decrease of forward scatter, increase of annexin-V-binding and enhanced ceramide formation.	Novobiocin	32-42	annexin A5	Homo sapiens	150-159
24096869-5	2013	Specifically, we show that the Hsp90 inhibitors geldanamycin and novobiocin efficiently impede the differentiation of murine 3T3-L1 preadipocytes.	Novobiocin	65-75	heat shock protein 86, pseudogene 2	Mus musculus	31-36
24900777-2	2014	Currently, the majority of Hsp90 C-terminal inhibitors are derived from novobiocin, a natural product traditionally used as an antibiotic.	Novobiocin	72-82	heat shock protein 90 alpha family class A member 1	Homo sapiens	27-32
24900777-3	2014	Assisted by molecular docking studies, a scaffold containing a biphenyl moiety in lieu of the coumarin ring system found in novobiocin was identified for development of new Hsp90 C-terminal inhibitors.	Novobiocin	124-134	heat shock protein 90 alpha family class A member 1	Homo sapiens	173-178
24466266-6	2014	Treatment of cells with novobiocin led to internalization of FN into vesicles that were positive for the presence of the lysosomal marker, LAMP-1.	Novobiocin	24-34	fibronectin 1	Homo sapiens	61-63
24466266-6	2014	Treatment of cells with novobiocin led to internalization of FN into vesicles that were positive for the presence of the lysosomal marker, LAMP-1.	Novobiocin	24-34	lysosomal associated membrane protein 1	Homo sapiens	139-145
24643001-8	2014	Removal of extracellular Ca(2+) virtually abrogated the increase of annexin-V-binding following novobiocin exposure.	Novobiocin	96-106	annexin A5	Homo sapiens	68-77
24127661-9	2013	Novobiocin analogues that revealed activity in this assay were examined via western blot experiments for client protein degradation, a hallmark of Hsp90 inhibition.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	147-152
23859777-1	2013	Recent studies have shown that novobiocin (NB), a member of the coumermycin (CA) family of antibiotics with demonstrated DNA gyrase inhibitory activity, inhibits Heat shock protein 90 (HSP90) by binding weakly to a putative ATP-binding site within its C-terminus.	Novobiocin	31-41	DNA topoisomerase II alpha	Homo sapiens	121-131
23859777-1	2013	Recent studies have shown that novobiocin (NB), a member of the coumermycin (CA) family of antibiotics with demonstrated DNA gyrase inhibitory activity, inhibits Heat shock protein 90 (HSP90) by binding weakly to a putative ATP-binding site within its C-terminus.	Novobiocin	31-41	heat shock protein 90 alpha family class A member 1	Homo sapiens	162-183
23859777-1	2013	Recent studies have shown that novobiocin (NB), a member of the coumermycin (CA) family of antibiotics with demonstrated DNA gyrase inhibitory activity, inhibits Heat shock protein 90 (HSP90) by binding weakly to a putative ATP-binding site within its C-terminus.	Novobiocin	31-41	heat shock protein 90 alpha family class A member 1	Homo sapiens	185-190
23671581-0	2013	A novel function of novobiocin: disrupting the interaction of HIF 1alpha and p300/CBP through direct binding to the HIF1alpha C-terminal activation domain.	Novobiocin	20-30	hypoxia inducible factor 1 subunit alpha	Homo sapiens	62-72
23671581-0	2013	A novel function of novobiocin: disrupting the interaction of HIF 1alpha and p300/CBP through direct binding to the HIF1alpha C-terminal activation domain.	Novobiocin	20-30	E1A binding protein p300	Homo sapiens	77-81
23671581-0	2013	A novel function of novobiocin: disrupting the interaction of HIF 1alpha and p300/CBP through direct binding to the HIF1alpha C-terminal activation domain.	Novobiocin	20-30	CREB binding protein	Homo sapiens	82-85
23671581-0	2013	A novel function of novobiocin: disrupting the interaction of HIF 1alpha and p300/CBP through direct binding to the HIF1alpha C-terminal activation domain.	Novobiocin	20-30	hypoxia inducible factor 1 subunit alpha	Homo sapiens	116-125
23671581-4	2013	Here, we document, for the first time, that the aminocoumarin antibiotic, novobiocin, directly blocks the protein-protein interaction between the HIF1alpha C-terminal activation domain (CTAD) and the cysteine-histidine rich (CH1) region of p300/CBP.	Novobiocin	74-84	hypoxia inducible factor 1 subunit alpha	Homo sapiens	146-155
23671581-4	2013	Here, we document, for the first time, that the aminocoumarin antibiotic, novobiocin, directly blocks the protein-protein interaction between the HIF1alpha C-terminal activation domain (CTAD) and the cysteine-histidine rich (CH1) region of p300/CBP.	Novobiocin	74-84	E1A binding protein p300	Homo sapiens	240-244
23671581-4	2013	Here, we document, for the first time, that the aminocoumarin antibiotic, novobiocin, directly blocks the protein-protein interaction between the HIF1alpha C-terminal activation domain (CTAD) and the cysteine-histidine rich (CH1) region of p300/CBP.	Novobiocin	74-84	CREB binding protein	Homo sapiens	245-248
23671581-5	2013	Also, novobiocin down-regulated HIF1alpha-controlled gene expression, specifically CA9, which is related to tumorigenesis.	Novobiocin	6-16	hypoxia inducible factor 1 subunit alpha	Homo sapiens	32-41
23671581-5	2013	Also, novobiocin down-regulated HIF1alpha-controlled gene expression, specifically CA9, which is related to tumorigenesis.	Novobiocin	6-16	carbonic anhydrase 9	Homo sapiens	83-86
23671581-7	2013	Rescue experiments revealed that the recombinant CTAD fragment of HIF1alpha partially reversed novobiocin"s inhibitory effects on cell proliferation and colony formation in MCF-7 cells.	Novobiocin	95-105	hypoxia inducible factor 1 subunit alpha	Homo sapiens	66-75
22702513-1	2012	Compound 2 (KU-32) is a first-generation novologue (a novobiocin-based, C-terminal, heat shock protein 90 (Hsp90) inhibitor) that decreases glucose-induced death of primary sensory neurons and reverses numerous clinical indices of diabetic peripheral neuropathy in mice.	Novobiocin	54-64	heat shock protein, 3	Mus musculus	84-105
23234644-2	2013	Novobiocin is the first Hsp90 C-terminal inhibitor ever identified and recent structure-activity relationship studies on the noviose sugar identified several commercially available amines as suitable surrogates.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	24-29
23129443-7	2012	The target of AMM has been proved to be the DNA gyrase B subunit and its binding mode to DNA gyrase is different from those of novobiocin and coumermycin, the known DNA gyrase inhibitors.	Novobiocin	127-137	DNA topoisomerase II alpha	Homo sapiens	44-54
22934946-7	2013	As an illustration, we describe the results of a cellbased study of the cytotoxicity of 24 analogs of novobiocin, a C-terminal inhibitor of heat shock protein 90 (Hsp90); the compounds were ranked in order of cytotoxicity to a panel of 18 cancer cell lines and 1 normal cell line.	Novobiocin	102-112	heat shock protein 90 alpha family class A member 1	Homo sapiens	140-161
22934946-7	2013	As an illustration, we describe the results of a cellbased study of the cytotoxicity of 24 analogs of novobiocin, a C-terminal inhibitor of heat shock protein 90 (Hsp90); the compounds were ranked in order of cytotoxicity to a panel of 18 cancer cell lines and 1 normal cell line.	Novobiocin	102-112	heat shock protein 90 alpha family class A member 1	Homo sapiens	163-168
22702513-1	2012	Compound 2 (KU-32) is a first-generation novologue (a novobiocin-based, C-terminal, heat shock protein 90 (Hsp90) inhibitor) that decreases glucose-induced death of primary sensory neurons and reverses numerous clinical indices of diabetic peripheral neuropathy in mice.	Novobiocin	54-64	heat shock protein, 3	Mus musculus	107-112
23606927-2	2012	Extensive structural modifications to novobiocin, the first Hsp90 C-terminal inhibitor discovered, have produced a library of novobiocin analogues and revealed some structure-activity relationships.	Novobiocin	38-48	heat shock protein 90 alpha family class A member 1	Homo sapiens	60-65
22413817-2	2012	KU-32 is a novobiocin-based, C-terminal inhibitor of the molecular chaperone, heat shock protein 90 (Hsp90).	Novobiocin	11-21	heat shock protein 90 alpha family class A member 1	Homo sapiens	78-99
22413817-2	2012	KU-32 is a novobiocin-based, C-terminal inhibitor of the molecular chaperone, heat shock protein 90 (Hsp90).	Novobiocin	11-21	heat shock protein 90 alpha family class A member 1	Homo sapiens	101-106
23316269-2	2012	KU-398, a novobiocin analogue, and silybin were recently identified as new Hsp90 inhibitors.	Novobiocin	10-20	heat shock protein 90 alpha family class A member 1	Homo sapiens	75-80
21924824-2	2011	We investigated a novobiocin-derived Hsp90 C-terminal inhibitor, KU135, for anti-proliferative effects in melanoma cells.	Novobiocin	18-28	heat shock protein 90 alpha family class A member 1	Homo sapiens	37-42
23197975-1	2012	KU-32 is a novel, novobiocin-based Hsp90 inhibitor that protects against neuronal glucotoxicity and reverses multiple clinical indices of diabetic peripheral neuropathy in a rodent model.	Novobiocin	18-28	heat shock protein 90 alpha family class A member 1	Homo sapiens	35-40
22004293-11	2011	Inhibition of Hsp90beta by the chemicals Geldanamycin (GA) and Novobiocin (NB) caused a dose-dependent decrease of the NO production induced by IL-1beta in chondrocytes, up to basal levels.	Novobiocin	63-73	heat shock protein 90 alpha family class B member 1	Homo sapiens	14-23
22014546-0	2011	Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.	Novobiocin	48-58	heat shock protein 90 alpha family class A member 1	Homo sapiens	70-75
22014546-1	2011	Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for Hsp90 inhibitory activity.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	101-106
22004293-11	2011	Inhibition of Hsp90beta by the chemicals Geldanamycin (GA) and Novobiocin (NB) caused a dose-dependent decrease of the NO production induced by IL-1beta in chondrocytes, up to basal levels.	Novobiocin	63-73	interleukin 1 beta	Homo sapiens	144-152
21755987-2	2011	Novobiocin, a typically C-terminal inhibitor for Hsp90, will probably used as an important anticancer drug in the future.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	49-54
21256827-8	2011	The HP0859 knockout mutant exhibited a severe truncation of LPS, a decreased growth rate, and a higher susceptibility to novobiocin.	Novobiocin	121-131	ADP-glyceromanno-heptose 6-epimerase	Helicobacter pylori 26695	4-10
21627535-5	2011	It was demonstrated, using a range of primary and transformed mesothelial and mesothelioma cell lines, that cells assembled high molecular weight kininogen and plasma prekallikrein to liberate bradykinin, a process inhibited by novobiocin, a heat shock protein 90 (HSP90) inhibitor, cysteine, bradykinin and protamine sulphate.	Novobiocin	228-238	kininogen 1	Homo sapiens	193-203
21627535-5	2011	It was demonstrated, using a range of primary and transformed mesothelial and mesothelioma cell lines, that cells assembled high molecular weight kininogen and plasma prekallikrein to liberate bradykinin, a process inhibited by novobiocin, a heat shock protein 90 (HSP90) inhibitor, cysteine, bradykinin and protamine sulphate.	Novobiocin	228-238	heat shock protein 90 alpha family class A member 1	Homo sapiens	242-263
21627535-5	2011	It was demonstrated, using a range of primary and transformed mesothelial and mesothelioma cell lines, that cells assembled high molecular weight kininogen and plasma prekallikrein to liberate bradykinin, a process inhibited by novobiocin, a heat shock protein 90 (HSP90) inhibitor, cysteine, bradykinin and protamine sulphate.	Novobiocin	228-238	heat shock protein 90 alpha family class A member 1	Homo sapiens	265-270
21627535-5	2011	It was demonstrated, using a range of primary and transformed mesothelial and mesothelioma cell lines, that cells assembled high molecular weight kininogen and plasma prekallikrein to liberate bradykinin, a process inhibited by novobiocin, a heat shock protein 90 (HSP90) inhibitor, cysteine, bradykinin and protamine sulphate.	Novobiocin	228-238	kininogen 1	Homo sapiens	293-303
21553822-1	2011	Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety.	Novobiocin	41-51	heat shock protein 90 alpha family class A member 1	Homo sapiens	70-75
21553822-3	2011	Utilization of structure-activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest midnanomolar activity against a panel of cancer cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.	Novobiocin	70-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	261-266
21419530-5	2011	In the ATPase inhibitory test, ATP hydrolysis was reduced less efficiently by compound 14 (28.5+-4.6%) than novobiocin (60.4+-8.1%).	Novobiocin	108-118	dynein axonemal heavy chain 8	Homo sapiens	7-13
20159978-5	2010	Experimental manipulation of Hsp90 function by the inhibitor novobiocin, but not 17-AAG, results in redistribution of AF9 from a primarily nuclear to cytoplasmic location.	Novobiocin	61-71	heat shock protein 90 alpha family class A member 1	Homo sapiens	29-34
20692357-7	2010	Inhibition of Hsp90 function by geldanamycin derivatives and novobiocin elicited a pattern of HSF1 activation and BAG3 expression that was similar to PDTC.	Novobiocin	61-71	heat shock transcription factor 1	Homo sapiens	94-98
20692357-7	2010	Inhibition of Hsp90 function by geldanamycin derivatives and novobiocin elicited a pattern of HSF1 activation and BAG3 expression that was similar to PDTC.	Novobiocin	61-71	BAG cochaperone 3	Homo sapiens	114-118
20536386-7	2010	HK-PPK activation was inhibited by cysteine, BK and protamine, and by novobiocin, a heat shock protein 90 (HSP90) inhibitor.	Novobiocin	70-80	kininogen 1	Homo sapiens	0-2
20536386-7	2010	HK-PPK activation was inhibited by cysteine, BK and protamine, and by novobiocin, a heat shock protein 90 (HSP90) inhibitor.	Novobiocin	70-80	kallikrein B1	Homo sapiens	3-6
20536386-7	2010	HK-PPK activation was inhibited by cysteine, BK and protamine, and by novobiocin, a heat shock protein 90 (HSP90) inhibitor.	Novobiocin	70-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	84-105
20536386-7	2010	HK-PPK activation was inhibited by cysteine, BK and protamine, and by novobiocin, a heat shock protein 90 (HSP90) inhibitor.	Novobiocin	70-80	heat shock protein 90 alpha family class A member 1	Homo sapiens	107-112
21904660-1	2010	Structural modifications to the coumarin core and benzamide side chain of novobiocin have successfully transformed the natural product from a selective DNA gyrase inhibitor into a potent inhibitor of the Hsp90 C-terminus.	Novobiocin	74-84	DNA topoisomerase II alpha	Homo sapiens	152-162
21904660-1	2010	Structural modifications to the coumarin core and benzamide side chain of novobiocin have successfully transformed the natural product from a selective DNA gyrase inhibitor into a potent inhibitor of the Hsp90 C-terminus.	Novobiocin	74-84	heat shock protein 90 alpha family class A member 1	Homo sapiens	204-209
20570149-0	2010	Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.	Novobiocin	92-102	heat shock protein 90 alpha family class A member 1	Homo sapiens	25-30
21129982-1	2011	Several Hsp90 modulators have been identified including the N-terminal ligand geldanamycin (GDA), the C-terminal ligand novobiocin (NB), and the co-chaperone disruptor celastrol.	Novobiocin	120-130	heat shock protein 90 alpha family class A member 1	Homo sapiens	8-13
20632361-9	2010	The results of this study suggest that the category of BCRP-specific inhibitors, which includes only fumitremorgin C, Ko143 and analogues, and novobiocin needs to be extended by this new class of inhibitors, which possess three key characteristics: specificity, potency, and low toxicity.	Novobiocin	143-153	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	55-59
20159978-5	2010	Experimental manipulation of Hsp90 function by the inhibitor novobiocin, but not 17-AAG, results in redistribution of AF9 from a primarily nuclear to cytoplasmic location.	Novobiocin	61-71	MLLT3 super elongation complex subunit	Homo sapiens	118-121
20159978-6	2010	Knockdown of Hsp90 with siRNA mimics the effect elicited by novobiocin.	Novobiocin	60-70	heat shock protein 90 alpha family class A member 1	Homo sapiens	13-18
19739131-2	2010	Previously, we reported the development of novobiocin analogues designed to inhibit the C-terminal portion of Hsp90, which demonstrated the ability to decrease client protein expression.	Novobiocin	43-53	heat shock protein 90 alpha family class A member 1	Homo sapiens	110-115
20039369-0	2010	Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.	Novobiocin	0-10	SET and MYND domain containing 3	Homo sapiens	21-26
20039369-3	2010	In this study, we further found that novobiocin, a HSP90 inhibitor, could decrease the expression of SMYD3 and dose dependently inhibit the proliferation and migration of MDA-MB-231 human breast cancer cells.	Novobiocin	37-47	heat shock protein 90 alpha family class A member 1	Homo sapiens	51-56
20039369-3	2010	In this study, we further found that novobiocin, a HSP90 inhibitor, could decrease the expression of SMYD3 and dose dependently inhibit the proliferation and migration of MDA-MB-231 human breast cancer cells.	Novobiocin	37-47	SET and MYND domain containing 3	Homo sapiens	101-106
20039369-5	2010	This study is the first to show that novobiocin can inhibit the migration of breast cancer cells and such event may involve the downregulation of SMYD3.	Novobiocin	37-47	SET and MYND domain containing 3	Homo sapiens	146-151
20307139-5	2010	BCRP activity was determined flow cytometrically by measuring mitoxantrone accumulation in the absence and presence of the inhibitor, novobiocin.	Novobiocin	134-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-4
19932969-1	2010	The natural products novobiocin and derrubone have both demonstrated Hsp90 inhibition and structure-activity relationships have been established for each scaffold.	Novobiocin	21-31	heat shock protein 90 alpha family class A member 1	Homo sapiens	69-74
19932969-4	2010	These studies confirmed that the functionality present at the 3-position of the isoflavone plays a critical role in determining Hsp90 inhibition and suggests that the bicyclic ring system present in both novobiocin and derrubone do not share similar modes of binding.	Novobiocin	204-214	heat shock protein 90 alpha family class A member 1	Homo sapiens	128-133
19935870-0	2009	Modulation of Hsf1 activity by novobiocin and geldanamycin.	Novobiocin	31-41	heat shock factor protein	Xenopus laevis	14-18
19935870-1	2009	Since Hsp90 is a known modulator of HSF1 activity, we examined the effects of two pharmacological inhibitors of Hsp90, novobiocin and geldanamycin, on HSF1 DNA-binding activity in the Xenopus oocyte model system.	Novobiocin	119-129	heat shock factor protein	Xenopus laevis	151-155
19935870-2	2009	Novobiocin exhibits antiproliferative activity in culture cells and interacts with a C-terminal ATP-binding pocket on Hsp90, inhibiting Hsp90 autophosphorylation.	Novobiocin	0-10	heat shock protein HSP 90-beta	Xenopus laevis	118-123
19935870-2	2009	Novobiocin exhibits antiproliferative activity in culture cells and interacts with a C-terminal ATP-binding pocket on Hsp90, inhibiting Hsp90 autophosphorylation.	Novobiocin	0-10	heat shock protein HSP 90-beta	Xenopus laevis	136-141
19935870-3	2009	Treatment of oocytes with novobiocin followed by heat shock results in a dose-dependent decrease in HSF1 DNA-binding and transcriptional activity.	Novobiocin	26-36	heat shock factor protein	Xenopus laevis	100-104
19935870-8	2009	The data obtained with novobiocin suggests the C-terminal ATP-binding activity of Hsp90 is required for the initial steps of HSF1 trimerization, whereas the effects of geldanamycin suggest N-terminal ATPase and chaperone activities are required for disassembly of activated trimers.	Novobiocin	23-33	heat shock protein HSP 90-beta	Xenopus laevis	82-87
19741006-3	2009	Here, we investigated the extent to which a novel novobiocin-derived C-terminal Hsp90 inhibitor, designated KU135, induced antiproliferative effects in Jurkat T-lymphocytes.	Novobiocin	50-60	heat shock protein 90 alpha family class A member 1	Homo sapiens	80-85
19374378-1	2009	Complexes of the antibiotics novobiocin and clorobiocin with DNA gyrase are illustrative of the importance of bound water to binding thermodynamics.	Novobiocin	29-39	DNA topoisomerase II alpha	Homo sapiens	61-71
19282394-4	2009	In the current study, we characterized the inhibitory effects of novobiocin on the function of human OATs (hOAT)1, hOAT3, and hOAT4.	Novobiocin	65-75	solute carrier family 22 member 6	Homo sapiens	107-113
19282394-4	2009	In the current study, we characterized the inhibitory effects of novobiocin on the function of human OATs (hOAT)1, hOAT3, and hOAT4.	Novobiocin	65-75	solute carrier family 22 member 8	Homo sapiens	115-120
19282394-4	2009	In the current study, we characterized the inhibitory effects of novobiocin on the function of human OATs (hOAT)1, hOAT3, and hOAT4.	Novobiocin	65-75	solute carrier family 22 member 11	Homo sapiens	126-131
19282394-5	2009	Kinetic study revealed that novobiocin inhibited OAT-mediated uptake in a competitive manner, with K(i) of 14.87 +/- 0.40 microM for hOAT1, K(i) of 4.77 +/- 1.12 microM for hOAT3, and K(i) of 90.50 +/- 7.50 microM for hOAT4.	Novobiocin	28-38	solute carrier family 22 member 6	Homo sapiens	133-138
19282394-5	2009	Kinetic study revealed that novobiocin inhibited OAT-mediated uptake in a competitive manner, with K(i) of 14.87 +/- 0.40 microM for hOAT1, K(i) of 4.77 +/- 1.12 microM for hOAT3, and K(i) of 90.50 +/- 7.50 microM for hOAT4.	Novobiocin	28-38	solute carrier family 22 member 8	Homo sapiens	173-178
19282394-5	2009	Kinetic study revealed that novobiocin inhibited OAT-mediated uptake in a competitive manner, with K(i) of 14.87 +/- 0.40 microM for hOAT1, K(i) of 4.77 +/- 1.12 microM for hOAT3, and K(i) of 90.50 +/- 7.50 microM for hOAT4.	Novobiocin	28-38	solute carrier family 22 member 11	Homo sapiens	218-223
18939877-1	2008	Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-terminus and induces degradation of Hsp90-dependent client proteins at approximately 700 microM in breast cancer cells (SKBr3).	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	92-97
19258280-4	2009	The inactivation of the mexB gene (which codes for the RND transporter MexB) in the 11 selected strains showed that the Tic(hs) phenotype was due to a mutational or functional loss of function of MexAB-OprM, the multidrug efflux system known to contribute to the natural resistance of P. aeruginosa to beta-lactams (e.g., ticarcillin and aztreonam), fluoroquinolones, tetracycline, and novobiocin.	Novobiocin	386-396	multidrug resistance protein MexB	Pseudomonas aeruginosa PAO1	24-28
19258280-4	2009	The inactivation of the mexB gene (which codes for the RND transporter MexB) in the 11 selected strains showed that the Tic(hs) phenotype was due to a mutational or functional loss of function of MexAB-OprM, the multidrug efflux system known to contribute to the natural resistance of P. aeruginosa to beta-lactams (e.g., ticarcillin and aztreonam), fluoroquinolones, tetracycline, and novobiocin.	Novobiocin	386-396	multidrug resistance protein MexB	Pseudomonas aeruginosa PAO1	71-75
18842335-1	2009	We evaluated whether inhibition of heat shock protein 90 (hsp90) function by novobiocin derivatives could induce the degradation of signal transducers that drive cancer cell growth and thereby promote apoptosis.	Novobiocin	77-87	heat shock protein 90 alpha family class A member 1	Homo sapiens	35-56
18842335-1	2009	We evaluated whether inhibition of heat shock protein 90 (hsp90) function by novobiocin derivatives could induce the degradation of signal transducers that drive cancer cell growth and thereby promote apoptosis.	Novobiocin	77-87	heat shock protein 90 alpha family class A member 1	Homo sapiens	58-63
19187436-3	2009	Treatment of SH-SY5Y neuroblastoma cells and human embryonic kidney cells with the HSP90 inhibitors novobiocin and geldanamycin caused substantial decreases in the level of Akt in the mitochondria without affecting the level of Akt in the cytosol.	Novobiocin	100-110	heat shock protein 90 alpha family class A member 1	Homo sapiens	83-88
19187436-3	2009	Treatment of SH-SY5Y neuroblastoma cells and human embryonic kidney cells with the HSP90 inhibitors novobiocin and geldanamycin caused substantial decreases in the level of Akt in the mitochondria without affecting the level of Akt in the cytosol.	Novobiocin	100-110	AKT serine/threonine kinase 1	Homo sapiens	173-176
19187436-3	2009	Treatment of SH-SY5Y neuroblastoma cells and human embryonic kidney cells with the HSP90 inhibitors novobiocin and geldanamycin caused substantial decreases in the level of Akt in the mitochondria without affecting the level of Akt in the cytosol.	Novobiocin	100-110	AKT serine/threonine kinase 1	Homo sapiens	228-231
19187436-4	2009	Moreover, intracerebroventricular injection of novobiocin into mice brains decreased Akt levels in cortical mitochondria.	Novobiocin	47-57	thymoma viral proto-oncogene 1	Mus musculus	85-88
19187436-9	2009	This effect was blocked when Akt was mostly excluded from the mitochondria with novobiocin treatment.	Novobiocin	80-90	AKT serine/threonine kinase 1	Homo sapiens	29-32
18939877-1	2008	Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-terminus and induces degradation of Hsp90-dependent client proteins at approximately 700 microM in breast cancer cells (SKBr3).	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	136-141
18847278-2	2008	Exploration of actinomycetes for isolation of natural products for abrogating TRAIL resistance led to the isolation of two new tyrosine derivatives (1 and 2) along with novobiocin (3).	Novobiocin	169-179	TNF superfamily member 10	Homo sapiens	78-83
18304811-0	2008	Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).	Novobiocin	79-89	heat shock protein 90 alpha family class A member 1	Homo sapiens	114-135
18690239-6	2008	Addition of increasing concentrations of clinically validated novobiocin (Albamycin) dissociated the GyrB subunits, thereby resulting in dissociation of the hydrogel and dose- and time-dependent liberation of the entrapped protein pharmaceutical VEGF(121) for triggering proliferation of human umbilical vein endothelial cells.	Novobiocin	62-72	vascular endothelial growth factor A	Homo sapiens	246-250
18690239-6	2008	Addition of increasing concentrations of clinically validated novobiocin (Albamycin) dissociated the GyrB subunits, thereby resulting in dissociation of the hydrogel and dose- and time-dependent liberation of the entrapped protein pharmaceutical VEGF(121) for triggering proliferation of human umbilical vein endothelial cells.	Novobiocin	74-83	vascular endothelial growth factor A	Homo sapiens	246-250
18418407-0	2008	Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.	Novobiocin	123-133	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	18-25
18418407-0	2008	Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.	Novobiocin	123-133	heat shock protein 90 alpha family class A member 1	Homo sapiens	26-31
18418407-0	2008	Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.	Novobiocin	123-133	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	81-88
18218611-8	2008	Gamendazole binding to purified Saccharomyces cerevisiae HSP82 inhibited luciferase refolding and was not competed by the HSP90 drugs geldanamycin or novobiocin analogue, KU-1.	Novobiocin	150-160	Hsp90 family chaperone HSP82	Saccharomyces cerevisiae S288C	57-62
18359116-4	2008	When cells were treated with an Hsp90 inhibitor (geldanamycin or novobiocin), levels of PINK1 were greatly diminished, reflecting its rapid degradation via ubiquitin-proteasome pathway.	Novobiocin	65-75	heat shock protein 90 alpha family class A member 1	Homo sapiens	32-37
18359116-4	2008	When cells were treated with an Hsp90 inhibitor (geldanamycin or novobiocin), levels of PINK1 were greatly diminished, reflecting its rapid degradation via ubiquitin-proteasome pathway.	Novobiocin	65-75	PTEN induced kinase 1	Homo sapiens	88-93
18304811-0	2008	Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).	Novobiocin	79-89	heat shock protein 90 alpha family class A member 1	Homo sapiens	137-142
18293999-1	2008	Recent studies have shown that the DNA gyrase inhibitor, novobiocin, binds to a previously unrecognized ATP-binding site located at the C-terminus of Hsp90 and induces degradation of Hsp90-dependent client proteins at approximately 700 microM.	Novobiocin	57-67	heat shock protein 90 alpha family class A member 1	Homo sapiens	150-155
18293999-1	2008	Recent studies have shown that the DNA gyrase inhibitor, novobiocin, binds to a previously unrecognized ATP-binding site located at the C-terminus of Hsp90 and induces degradation of Hsp90-dependent client proteins at approximately 700 microM.	Novobiocin	57-67	heat shock protein 90 alpha family class A member 1	Homo sapiens	183-188
18093089-0	2008	Transferred NOE and saturation transfer difference NMR studies of novobiocin binding to EnvZ suggest binding mode similar to DNA gyrase.	Novobiocin	66-76	DNA topoisomerase II alpha	Homo sapiens	125-135
18066713-3	2008	When coincubating A549 with LPS and meta-iodobenzylguanidine or novobiocin, selective arginine-dependent ART-inhibitors, the release of IL-6 and IL-8 was inhibited in a concentration-dependent manner.	Novobiocin	64-74	interleukin 6	Homo sapiens	136-140
18066713-3	2008	When coincubating A549 with LPS and meta-iodobenzylguanidine or novobiocin, selective arginine-dependent ART-inhibitors, the release of IL-6 and IL-8 was inhibited in a concentration-dependent manner.	Novobiocin	64-74	C-X-C motif chemokine ligand 8	Homo sapiens	145-149
18347135-5	2008	Likewise, established Hsp90 inhibitors (17-allylamino-geldanamycin and novobiocin) repress PTTG1/Securin gene expression.	Novobiocin	71-81	heat shock protein 90 alpha family class A member 1	Homo sapiens	22-27
18347135-5	2008	Likewise, established Hsp90 inhibitors (17-allylamino-geldanamycin and novobiocin) repress PTTG1/Securin gene expression.	Novobiocin	71-81	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	91-96
18347135-5	2008	Likewise, established Hsp90 inhibitors (17-allylamino-geldanamycin and novobiocin) repress PTTG1/Securin gene expression.	Novobiocin	71-81	PTTG1 regulator of sister chromatid separation, securin	Homo sapiens	97-104
18047824-2	2008	Binding to the exposed C terminus on the Hsp90alpha(NT) column was characterized using frontal chromatography and the C-terminus ligands coumermycin A(1) (CA1) and novobiocin (NOVO).	Novobiocin	164-174	heat shock protein 90 alpha family class A member 1	Homo sapiens	41-51
18093089-4	2008	DNA Gyrase B has several well-characterized potent inhibitors, including novobiocin and clorobiocin which have detailed structures in complex.	Novobiocin	73-83	DNA topoisomerase II alpha	Homo sapiens	0-10
18991631-0	2008	Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	44-49
18991631-36	2008	This review describes the different C-terminal inhibitors of Hsp90, with specific emphasis on structure-activity relationship studies of novobiocin and their effects on anti-proliferative activity.	Novobiocin	137-147	heat shock protein 86, pseudogene 2	Mus musculus	61-66
18991631-13	2008	Novobiocin was reported to bind weakly to the newly discovered Hsp90 C-terminal ATP binding site ( approximately 700 M in SkBr3 cells) and induce degradation of Hsp90 client proteins.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	63-68
18991631-13	2008	Novobiocin was reported to bind weakly to the newly discovered Hsp90 C-terminal ATP binding site ( approximately 700 M in SkBr3 cells) and induce degradation of Hsp90 client proteins.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	161-166
18991631-27	2008	Similar to novobiocin, EGCG was shown to bind the C-terminus of Hsp90.	Novobiocin	11-21	heat shock protein 86, pseudogene 2	Mus musculus	64-69
17923155-7	2008	Functional studies demonstrated significant increases in the intra-vesicular accumulation of [(3)H]-glyburide in vesicles treated with the BCRP inhibitor, novobiocin.	Novobiocin	155-165	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	139-143
18159130-5	2007	When ABCG2 was inhibited by imatinib or novobiocin, however, those cells became sensitive to light.	Novobiocin	40-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	5-10
17328573-1	2007	The DNA gyrase inhibitor, novobiocin, was recently shown to inhibit Hsp90 via a previously unrecognized C-terminal ATP-binding site.	Novobiocin	26-36	heat shock protein 90 alpha family class A member 1	Homo sapiens	68-73
17979263-2	2007	Investigation of novobiocin analogues lacking the noviose moiety as novel inhibitors of hsp90 was carried out.	Novobiocin	17-27	heat shock protein 90 alpha family class A member 1	Homo sapiens	88-93
17609257-9	2007	Finally, NBC content was related only to MCT1 content in soleus (r = 0.50, P < 0.01).	Novobiocin	9-12	solute carrier family 16 member 1	Rattus norvegicus	41-45
17276679-4	2007	We recently identified a small molecule novobiocin analogue, A4 that induces Hsp90 overexpression at low nanomolar concentrations and sought to test its neuroprotective properties.	Novobiocin	40-50	heat shock protein 90 alpha family class A member 1	Homo sapiens	77-82
16968702-5	2006	Hsp90 cross-linking to preprotein and coprecipitation of Hsp90 with Tom70 were both impaired by novobiocin.	Novobiocin	96-106	translocase of outer mitochondrial membrane 70	Homo sapiens	68-73
17132020-0	2006	Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.	Novobiocin	0-10	DNA topoisomerase II alpha	Homo sapiens	26-36
17132020-0	2006	Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	75-80
17132020-1	2006	Novobiocin is a member of the coumermycin family of antibiotics and is a well-established inhibitor of DNA gyrase.	Novobiocin	0-10	DNA topoisomerase II alpha	Homo sapiens	103-113
17132020-2	2006	Recent studies have shown that novobiocin binds to a previously unrecognized ATP-binding site at the C-terminus of Hsp90 and induces degradation of Hsp90-dependent client proteins at approximately 700 microM.	Novobiocin	31-41	heat shock protein 90 alpha family class A member 1	Homo sapiens	115-120
17132020-2	2006	Recent studies have shown that novobiocin binds to a previously unrecognized ATP-binding site at the C-terminus of Hsp90 and induces degradation of Hsp90-dependent client proteins at approximately 700 microM.	Novobiocin	31-41	heat shock protein 90 alpha family class A member 1	Homo sapiens	148-153
16460798-5	2006	Our results demonstrated significant increases in the intracellular accumulation of [(3)H]-glyburide in BCRP and MRP3 over-expressing cells in the presence of the inhibitors novobiocin and indomethacin, respectively.	Novobiocin	174-184	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	104-108
16460798-5	2006	Our results demonstrated significant increases in the intracellular accumulation of [(3)H]-glyburide in BCRP and MRP3 over-expressing cells in the presence of the inhibitors novobiocin and indomethacin, respectively.	Novobiocin	174-184	ATP binding cassette subfamily C member 3	Homo sapiens	113-117
16868863-3	2006	This is exemplified in this review for the biosynthetic gene clusters of the aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A (1), which are potent inhibitors of DNA gyrase.	Novobiocin	103-113	DNA topoisomerase II alpha	Homo sapiens	181-191
17073714-6	2006	Other inhibitors have recently been shown to bind to the C-terminal dimerization domain of Hsp90, such as cisplatin and novobiocin, or modify Hsp90 postranslationally, such as histone deacetylase or proteasome inhibitors.	Novobiocin	120-130	heat shock protein 90 alpha family class A member 1	Homo sapiens	91-96
16421106-4	2006	Prior incubation of the Hsp90 fragment with novobiocin led to a direct blockade of immunophilin cochaperone binding.	Novobiocin	44-54	heat shock protein 90 alpha family class A member 1	Homo sapiens	24-29
16968702-4	2006	Here, novobiocin was found to inhibit preprotein import and, in particular, targeting to the purified cytosolic fragment of Tom70.	Novobiocin	6-16	translocase of outer mitochondrial membrane 70	Homo sapiens	124-129
16968702-5	2006	Hsp90 cross-linking to preprotein and coprecipitation of Hsp90 with Tom70 were both impaired by novobiocin.	Novobiocin	96-106	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
16968702-5	2006	Hsp90 cross-linking to preprotein and coprecipitation of Hsp90 with Tom70 were both impaired by novobiocin.	Novobiocin	96-106	heat shock protein 90 alpha family class A member 1	Homo sapiens	57-62
16714764-5	2006	We also report that hsp90 inhibitors geldanamycin and novobiocin inhibit recombinant telomerase even after telomerase is assembled.	Novobiocin	54-64	heat shock protein 90 alpha family class A member 1	Homo sapiens	20-25
16714764-7	2006	Inhibition by novobiocin could not similarly be overcome but instead resulted in destabilization of the hTERT polypeptide.	Novobiocin	14-24	telomerase reverse transcriptase	Homo sapiens	104-109
16508638-7	2006	Treatment with the hsp-90 inhibitor novobiocin dissociated hsp90 and hTERT as revealed by immunoprecipitation and immunoblot analysis and reduced telomerase activity.	Novobiocin	36-46	heat shock protein 90 alpha family class A member 1	Homo sapiens	19-25
16508638-7	2006	Treatment with the hsp-90 inhibitor novobiocin dissociated hsp90 and hTERT as revealed by immunoprecipitation and immunoblot analysis and reduced telomerase activity.	Novobiocin	36-46	heat shock protein 90 alpha family class A member 1	Homo sapiens	59-64
16508638-7	2006	Treatment with the hsp-90 inhibitor novobiocin dissociated hsp90 and hTERT as revealed by immunoprecipitation and immunoblot analysis and reduced telomerase activity.	Novobiocin	36-46	telomerase reverse transcriptase	Homo sapiens	69-74
16421106-7	2006	Novobiocin also precluded the interaction of full-length Hsp90 with the p50(cdc37) cochaperone, which targets the N-terminal nucleotide-binding domain, and is prevalent in Hsp90 complexes with protein kinase substrates.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	57-62
16421106-7	2006	Novobiocin also precluded the interaction of full-length Hsp90 with the p50(cdc37) cochaperone, which targets the N-terminal nucleotide-binding domain, and is prevalent in Hsp90 complexes with protein kinase substrates.	Novobiocin	0-10	nuclear factor kappa B subunit 1	Homo sapiens	72-75
16421106-7	2006	Novobiocin also precluded the interaction of full-length Hsp90 with the p50(cdc37) cochaperone, which targets the N-terminal nucleotide-binding domain, and is prevalent in Hsp90 complexes with protein kinase substrates.	Novobiocin	0-10	cell division cycle 37, HSP90 cochaperone	Homo sapiens	76-81
16421106-7	2006	Novobiocin also precluded the interaction of full-length Hsp90 with the p50(cdc37) cochaperone, which targets the N-terminal nucleotide-binding domain, and is prevalent in Hsp90 complexes with protein kinase substrates.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	172-177
16421106-8	2006	Novobiocin therefore acts locally and allosterically to induce conformational changes within multiple regions of the Hsp90 protein.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	117-122
16421106-9	2006	We provide evidence that coumermycin A1, a coumarin structurally related to novobiocin, interferes with dimerization of the Hsp90 C-terminal domain.	Novobiocin	76-86	heat shock protein 90 alpha family class A member 1	Homo sapiens	124-129
16113273-10	2005	In vivo, the frequency of Rci-mediated inversion is influenced by the extent of DNA supercoiling, with increasing levels of expression of invertible genes as novobiocin inhibits DNA supercoiling and thus Rci action.	Novobiocin	158-168	shufflon-specific recombinase	Salmonella enterica	26-29
16842153-8	2006	Additional target-based screening uncovered novobiocin as a third structurally distinct small molecule with Hsp90 inhibitory properties.	Novobiocin	44-54	heat shock protein 90 alpha family class A member 1	Homo sapiens	108-113
16166072-3	2005	The capacity of these DNA tracts to undergo deletions-expansions was explored with three genetic-biochemical approaches including first, the utilization of topoisomerase I and/or DNA gyrase mutants, second, the specific inhibition of DNA gyrase by novobiocin, and third, the genetic removal of the HU protein, thus lowering the negative supercoil density (-sigma).	Novobiocin	248-258	DNA topoisomerase II alpha	Homo sapiens	234-244
16421106-0	2006	Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization.	Novobiocin	64-74	heat shock protein 90 alpha family class A member 1	Homo sapiens	103-108
16421106-2	2006	An alpha-helical region, upstream of the MEEVD peptide, helps form the dimerization interface and includes a hydrophobic microdomain that contributes to the Hsp90 interaction with the immunophilin cochaperones and corresponds to the binding site for novobiocin, a coumarin-related Hsp90 inhibitor.	Novobiocin	250-260	heat shock protein 90 alpha family class A member 1	Homo sapiens	157-162
16421106-2	2006	An alpha-helical region, upstream of the MEEVD peptide, helps form the dimerization interface and includes a hydrophobic microdomain that contributes to the Hsp90 interaction with the immunophilin cochaperones and corresponds to the binding site for novobiocin, a coumarin-related Hsp90 inhibitor.	Novobiocin	250-260	heat shock protein 90 alpha family class A member 1	Homo sapiens	281-286
15935620-7	2005	Surprisingly, short-term treatment of differentiating C2C12 with geldanamycin increased the phosphorylation of Akt on Ser473, an effect mimicked by treatment of C2C12 cells with okadaic acid or the Hsp90 inhibitor novobiocin.	Novobiocin	214-224	thymoma viral proto-oncogene 1	Mus musculus	111-114
15935620-7	2005	Surprisingly, short-term treatment of differentiating C2C12 with geldanamycin increased the phosphorylation of Akt on Ser473, an effect mimicked by treatment of C2C12 cells with okadaic acid or the Hsp90 inhibitor novobiocin.	Novobiocin	214-224	heat shock protein, 2	Mus musculus	198-203
16159253-0	2005	Hsp90 inhibitors identified from a library of novobiocin analogues.	Novobiocin	46-56	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
16159253-1	2005	Novobiocin is a C-terminal inhibitor of the Hsp90 protein folding machinery, which is responsible for the conformational maturation of numerous proteins involved in cancer growth and survival.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	44-49
16159253-3	2005	In this study, a parallel library of 20 novobiocin derivatives was prepared and the biological activity of each evaluated by Western blot analysis of Hsp90 client proteins.	Novobiocin	40-50	heat shock protein 90 alpha family class A member 1	Homo sapiens	150-155
16113273-10	2005	In vivo, the frequency of Rci-mediated inversion is influenced by the extent of DNA supercoiling, with increasing levels of expression of invertible genes as novobiocin inhibits DNA supercoiling and thus Rci action.	Novobiocin	158-168	shufflon-specific recombinase	Salmonella enterica	204-207
16128395-4	2005	SpvB-mediated actin degradation occurred in the presence of the serine protease inhibitor phenylmethylsulfonylfluoride (PMSF), but was inhibited upon addition of novobiocin, an inhibitor of mono (ADP-ribosyl)transferase activity, or upon addition of EDTA.	Novobiocin	162-172	virulence protein	Salmonella enterica	0-4
16061644-3	2005	Inhibition of BCRP-mediated efflux of dihydrotestosterone by novobiocin or fumitremorgin C in a rat prostate progenitor cell line that expresses BCRP and AR mRNAs, but minimal AR protein, results in stabilization and nuclear translocation of AR protein, providing a mechanism for lack of AR protein in BCRP-expressing stem cells.	Novobiocin	61-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	14-18
15501066-1	2004	Novobiocin was recently shown to inhibit Hsp90 through a previously unrecognized C-terminal ATP binding site.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	41-46
15501066-3	2004	In an effort to elucidate the C-terminal binding site of Hsp90, four photolabile analogues of novobiocin were prepared.	Novobiocin	94-104	heat shock protein 90 alpha family class A member 1	Homo sapiens	57-62
15634651-2	2004	To circumvent BCRP-mediated MDR, a common approach is the use of potent and specific inhibitors of BCRP transport such as fumitremorgin C, novobiocin, and GF120918.	Novobiocin	139-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	14-18
15634651-2	2004	To circumvent BCRP-mediated MDR, a common approach is the use of potent and specific inhibitors of BCRP transport such as fumitremorgin C, novobiocin, and GF120918.	Novobiocin	139-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	99-103
15209518-0	2004	Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	46-51
15471498-1	2004	Noviose is a key synthon for the construction of novobiocin, a clinically useful antitumor agent that has been shown to inhibit both type II topoisomerases and Hsp90.	Novobiocin	49-59	heat shock protein 90 alpha family class A member 1	Homo sapiens	160-165
15209518-8	2004	The recombinant C-terminal domain of Hsp90 adopted a proteolytic resistant conformation in the presence of novobiocin, indicating that alteration of Hsp90/cochaperone interactions was not the cause of the novobiocin-induced protease resistance within Hsp90"s C-terminal domain.	Novobiocin	107-117	heat shock protein 90 alpha family class A member 1	Homo sapiens	37-42
15209518-0	2004	Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	63-68
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	37-47	heat shock protein 90 alpha family class A member 1	Homo sapiens	112-117
15209518-3	2004	Recently, novobiocin has been shown to bind to a second nucleotide binding site located within the C-terminal domain of Hsp90.	Novobiocin	10-20	heat shock protein 90 alpha family class A member 1	Homo sapiens	120-125
15209518-4	2004	In this report, we have examined the effect of novobiocin on Hsp90 function in reticulocyte lysate.	Novobiocin	47-57	heat shock protein 90 alpha family class A member 1	Homo sapiens	61-66
15209518-5	2004	Novobiocin specifically inhibited the maturation of the heme-regulated eIF2alpha kinase (HRI) in a concentration-dependent manner.	Novobiocin	0-10	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	56-87
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	37-47	cell division cycle 37, HSP90 cochaperone	Homo sapiens	122-127
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	37-47	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	142-145
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	37-47	heat shock protein 90 alpha family class A member 1	Homo sapiens	183-188
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	37-47	cell division cycle 37, HSP90 cochaperone	Homo sapiens	189-194
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	37-47	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	219-222
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	150-160	cell division cycle 37, HSP90 cochaperone	Homo sapiens	122-127
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	150-160	heat shock protein 90 alpha family class A member 1	Homo sapiens	183-188
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	150-160	cell division cycle 37, HSP90 cochaperone	Homo sapiens	189-194
15209518-9	2004	The concentration dependence of this novobiocin-induced conformation change correlated with the dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition of Hsp90/Cdc37-dependent activation of HRI"s autokinase activity.	Novobiocin	150-160	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	219-222
15209518-10	2004	The data suggest that binding of novobiocin to the C-terminal nucleotide binding site of Hsp90 induces a change in Hsp90"s conformation leading to the dissociation of bound kinase.	Novobiocin	33-43	heat shock protein 90 alpha family class A member 1	Homo sapiens	89-94
15209518-10	2004	The data suggest that binding of novobiocin to the C-terminal nucleotide binding site of Hsp90 induces a change in Hsp90"s conformation leading to the dissociation of bound kinase.	Novobiocin	33-43	heat shock protein 90 alpha family class A member 1	Homo sapiens	115-120
15209518-5	2004	Novobiocin specifically inhibited the maturation of the heme-regulated eIF2alpha kinase (HRI) in a concentration-dependent manner.	Novobiocin	0-10	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	89-92
15209518-6	2004	Novobiocin induced the dissociation of Hsp90 and Cdc37 from immature HRI, while the Hsp90 cochaperones p23, FKBP52, and protein phosphatase 5 remained associated with immature HRI.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	39-44
15209518-6	2004	Novobiocin induced the dissociation of Hsp90 and Cdc37 from immature HRI, while the Hsp90 cochaperones p23, FKBP52, and protein phosphatase 5 remained associated with immature HRI.	Novobiocin	0-10	cell division cycle 37, HSP90 cochaperone	Homo sapiens	49-54
15209518-6	2004	Novobiocin induced the dissociation of Hsp90 and Cdc37 from immature HRI, while the Hsp90 cochaperones p23, FKBP52, and protein phosphatase 5 remained associated with immature HRI.	Novobiocin	0-10	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	69-72
15209518-6	2004	Novobiocin induced the dissociation of Hsp90 and Cdc37 from immature HRI, while the Hsp90 cochaperones p23, FKBP52, and protein phosphatase 5 remained associated with immature HRI.	Novobiocin	0-10	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	176-179
15209518-7	2004	Proteolytic fingerprinting of Hsp90 indicated that novobiocin had a distinct effect on the conformation of Hsp90, and molybdate lowered the concentration of novobiocin required to alter Hsp90"s conformation by 10-fold.	Novobiocin	51-61	heat shock protein 90 alpha family class A member 1	Homo sapiens	107-112
15209518-7	2004	Proteolytic fingerprinting of Hsp90 indicated that novobiocin had a distinct effect on the conformation of Hsp90, and molybdate lowered the concentration of novobiocin required to alter Hsp90"s conformation by 10-fold.	Novobiocin	51-61	heat shock protein 90 alpha family class A member 1	Homo sapiens	107-112
14618629-0	2004	Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.	Novobiocin	86-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	12-44
14618629-0	2004	Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.	Novobiocin	86-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	46-50
14618629-0	2004	Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.	Novobiocin	86-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	51-56
14618629-3	2004	Here we focused on drug efflux pump and examined whether novobiocin reversed drug resistance in multidrug-resistant cells highly expressing BCRP.	Novobiocin	57-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	140-144
14618629-8	2004	Novobiocin at 60 microM decreased the degree of the above resistance by approximately 26-fold in PC-6/SN2-5H2 cells, and similarly reversed resistance in MCF-7/MX, MCF-7/clone 8 and un-selected NCI-H460 cells highly expressing BCRP.	Novobiocin	0-10	proprotein convertase subtilisin/kexin type 5	Homo sapiens	97-101
14618629-8	2004	Novobiocin at 60 microM decreased the degree of the above resistance by approximately 26-fold in PC-6/SN2-5H2 cells, and similarly reversed resistance in MCF-7/MX, MCF-7/clone 8 and un-selected NCI-H460 cells highly expressing BCRP.	Novobiocin	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	227-231
14618629-9	2004	Furthermore, novobiocin increased the intracellular topotecan accumulation in these cells and inhibited the topotecan transport into the membrane vesicles of PC-6/SN2-5H2 cells.	Novobiocin	13-23	proprotein convertase subtilisin/kexin type 5	Homo sapiens	158-162
14618629-11	2004	The kinetic parameters in the transport study indicated that novobiocin was a inhibitor for BCRP, resulting in competitive inhibition of BCRP-mediated topotecan transport.	Novobiocin	61-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	92-96
14618629-11	2004	The kinetic parameters in the transport study indicated that novobiocin was a inhibitor for BCRP, resulting in competitive inhibition of BCRP-mediated topotecan transport.	Novobiocin	61-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	137-141
14612912-8	2003	Recently reported inhibitors of ABCG2 were evaluated and 50 microM novobiocin was found to reverse wild-type ABCG2 completely, but only reverse mutant ABCG2 partially.	Novobiocin	67-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	32-37
14668798-4	2003	Treatment of cells with either geldanamycin or novobiocin, two pharmacological inhibitors of Hsp90 causes the destabilization of LKB1.	Novobiocin	47-57	heat shock protein 90 alpha family class A member 1	Homo sapiens	93-98
14668798-4	2003	Treatment of cells with either geldanamycin or novobiocin, two pharmacological inhibitors of Hsp90 causes the destabilization of LKB1.	Novobiocin	47-57	serine/threonine kinase 11	Homo sapiens	129-133
14645686-8	2003	However, both Hsp90 isoforms were equally sensitive to the AhR-specific effects of novobiocin, which binds to the C terminus.	Novobiocin	83-93	Hsp90 family chaperone HSC82	Saccharomyces cerevisiae S288C	14-19
14612912-8	2003	Recently reported inhibitors of ABCG2 were evaluated and 50 microM novobiocin was found to reverse wild-type ABCG2 completely, but only reverse mutant ABCG2 partially.	Novobiocin	67-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	109-114
14612912-8	2003	Recently reported inhibitors of ABCG2 were evaluated and 50 microM novobiocin was found to reverse wild-type ABCG2 completely, but only reverse mutant ABCG2 partially.	Novobiocin	67-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	109-114
14730893-2	2003	METHODS: The anti-angiogenic activity of novobiocin was determined using chick embryo chorioallantoic membrane(CAM) assay.	Novobiocin	41-51	calmodulin 2	Gallus gallus	111-114
14730893-4	2003	RESULTS: Novobiocin at the doses of 100 and 200 micrograms/egg inhibited angiogenesis by 31.6% and 68.7% in CAM, respectively.	Novobiocin	9-19	calmodulin	Bos taurus	108-111
14730893-7	2003	In addition, novobiocin suppressed MMP-2 secretion, migration, and tube formation of endothelial cells.	Novobiocin	13-23	matrix metallopeptidase 2	Bos taurus	35-40
12876368-0	2003	Crystallization and preliminary X-ray studies on the putative dTDP sugar epimerase NovW from the novobiocin biosynthetic cluster of Streptomyces spheroides.	Novobiocin	97-107	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	62-66
12842893-4	2003	Inhibition of Hsp90 by geldanamycin, radicicol, cisplatin, and novobiocin induced a significant acceleration of detergent- and hypotonic shock-induced cell lysis.	Novobiocin	63-73	heat shock protein 90 alpha family class A member 1	Homo sapiens	14-19
14618629-12	2004	These findings suggest that novobiocin effectively overcomes BCRP-mediated drug resistance at acceptable concentrations.	Novobiocin	28-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	61-65
12678776-7	2003	Additional target-based screening uncovered novobiocin as a third structurally distinct small molecule with Hsp90 inhibitory properties.	Novobiocin	44-54	heat shock protein 90 alpha family class A member 1	Homo sapiens	108-113
12894535-0	2003	Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.	Novobiocin	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	22-26
12894535-0	2003	Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.	Novobiocin	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	27-30
12894535-0	2003	Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.	Novobiocin	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	31-35
12894535-5	2003	To investigate the possibility that novobiocin may enhance cytotoxicity in BCRP/MXR/ABCP overexpressing cells, we exposed MCF7/TPT300 cells to novobiocin.	Novobiocin	36-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	75-79
12894535-5	2003	To investigate the possibility that novobiocin may enhance cytotoxicity in BCRP/MXR/ABCP overexpressing cells, we exposed MCF7/TPT300 cells to novobiocin.	Novobiocin	36-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	80-83
12894535-5	2003	To investigate the possibility that novobiocin may enhance cytotoxicity in BCRP/MXR/ABCP overexpressing cells, we exposed MCF7/TPT300 cells to novobiocin.	Novobiocin	36-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	84-88
12146477-4	2002	Special reference must be made to novobiocin-sensitive coagulase-negative staphylococci, which represented more than 50% of the isolates and which elicited SCC geometric means of around 106/ml.	Novobiocin	34-44	SCC	Ovis aries	156-159
12586360-4	2003	Treatment of cells with novobiocin, which blocks C-terminal interaction of HSP90, disrupted HSP90 binding to Akt, induced Akt dephosphorylation and significantly reduced telomerase activity.	Novobiocin	24-34	heat shock protein 90 alpha family class A member 1	Homo sapiens	75-80
12586360-4	2003	Treatment of cells with novobiocin, which blocks C-terminal interaction of HSP90, disrupted HSP90 binding to Akt, induced Akt dephosphorylation and significantly reduced telomerase activity.	Novobiocin	24-34	heat shock protein 90 alpha family class A member 1	Homo sapiens	92-97
12586360-4	2003	Treatment of cells with novobiocin, which blocks C-terminal interaction of HSP90, disrupted HSP90 binding to Akt, induced Akt dephosphorylation and significantly reduced telomerase activity.	Novobiocin	24-34	AKT serine/threonine kinase 1	Homo sapiens	109-112
12586360-4	2003	Treatment of cells with novobiocin, which blocks C-terminal interaction of HSP90, disrupted HSP90 binding to Akt, induced Akt dephosphorylation and significantly reduced telomerase activity.	Novobiocin	24-34	AKT serine/threonine kinase 1	Homo sapiens	122-125
12586360-5	2003	The reduction of TERT activity by novobiocin was associated with an increase in apoptosis.	Novobiocin	34-44	telomerase reverse transcriptase	Homo sapiens	17-21
12586360-8	2003	To investigate whether the effect of novobiocin is due to the reduction of Akt or TERT phosphorylation, we overexpressed a phospho-mimetic, active Akt (T308D/S473D).	Novobiocin	37-47	AKT serine/threonine kinase 1	Homo sapiens	75-78
12586360-8	2003	To investigate whether the effect of novobiocin is due to the reduction of Akt or TERT phosphorylation, we overexpressed a phospho-mimetic, active Akt (T308D/S473D).	Novobiocin	37-47	telomerase reverse transcriptase	Homo sapiens	82-86
12586360-8	2003	To investigate whether the effect of novobiocin is due to the reduction of Akt or TERT phosphorylation, we overexpressed a phospho-mimetic, active Akt (T308D/S473D).	Novobiocin	37-47	AKT serine/threonine kinase 1	Homo sapiens	147-150
12586360-9	2003	Akt (T308D/S473D) prevented novobiocin-induced reduction of telomerase activity and the stimulation of apoptosis.	Novobiocin	28-38	AKT serine/threonine kinase 1	Homo sapiens	0-3
12586360-10	2003	Moreover, overexpression of a dominant negative PP2A construct (PP2A(L199P)) as well as incubation with the PP2A inhibitor okadaic acid blocked the inhibition of telomerase activity by novobiocin.	Novobiocin	185-195	protein phosphatase 2 phosphatase activator	Homo sapiens	48-52
12586360-10	2003	Moreover, overexpression of a dominant negative PP2A construct (PP2A(L199P)) as well as incubation with the PP2A inhibitor okadaic acid blocked the inhibition of telomerase activity by novobiocin.	Novobiocin	185-195	protein phosphatase 2 phosphatase activator	Homo sapiens	64-68
12586360-10	2003	Moreover, overexpression of a dominant negative PP2A construct (PP2A(L199P)) as well as incubation with the PP2A inhibitor okadaic acid blocked the inhibition of telomerase activity by novobiocin.	Novobiocin	185-195	protein phosphatase 2 phosphatase activator	Homo sapiens	64-68
12146477-6	2002	Finally, ewes infected by novobiocin-sensitive coagulase-negative staphylococci elicited SCC values similar to those of infections by major pathogens and milk yield losses ranging between those caused by minor and major pathogens.	Novobiocin	26-36	SCC	Ovis aries	89-92
10945979-0	2000	The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.	Novobiocin	37-47	heat shock protein 90 alpha family class A member 1	Homo sapiens	4-25
11853877-0	2002	Novobiocin is a novel inducer of CD38 on cells of the myelomonocytic lineage.	Novobiocin	0-10	CD38 molecule	Homo sapiens	33-37
11853877-2	2002	Novobiocin was found to increase CD38 expression (in all three cell lines) and to induce differentiation along the monocytic path in HL-60 and U-937 cells but not in KG-1a cells.	Novobiocin	0-10	CD38 molecule	Homo sapiens	33-37
12127946-0	2002	Evidence that the novobiocin-sensitive ATP-binding site of the heat shock protein 90 (hsp90) is necessary for its autophosphorylation.	Novobiocin	18-28	heat shock protein 90 alpha family class A member 1	Homo sapiens	63-84
12127946-0	2002	Evidence that the novobiocin-sensitive ATP-binding site of the heat shock protein 90 (hsp90) is necessary for its autophosphorylation.	Novobiocin	18-28	heat shock protein 90 alpha family class A member 1	Homo sapiens	86-91
12127946-8	2002	Recently it was shown that Hsp90 possesses a second ATP-binding site in the C-terminal region, which can be competed with novobiocin.	Novobiocin	122-132	heat shock protein 90 alpha family class A member 1	Homo sapiens	27-32
11779866-8	2002	Inhibition of the ATP-dependent chaperone activity of HSP90 by novobiocin or geldanamycin prevented heat-induced as well as hypoxia-induced HIF-1alpha accumulation, indicating a common role of the HSP90 chaperone activity in HIF-1alpha stabilization by these two environmental parameters.	Novobiocin	63-73	heat shock protein 90 alpha family class A member 1	Homo sapiens	54-59
11779866-8	2002	Inhibition of the ATP-dependent chaperone activity of HSP90 by novobiocin or geldanamycin prevented heat-induced as well as hypoxia-induced HIF-1alpha accumulation, indicating a common role of the HSP90 chaperone activity in HIF-1alpha stabilization by these two environmental parameters.	Novobiocin	63-73	hypoxia inducible factor 1 subunit alpha	Homo sapiens	140-150
11942117-5	2001	The samples were incubated in 225 ml of modified E. coli broth with novobiocin (mEC + n) at 42 degrees C for 4 h and the immunoassays were performed following the instructions of the manufacturer.	Novobiocin	68-78	chemokine (C-C motif) ligand 28	Mus musculus	80-83
10945979-5	2000	In the present study we used deletion/mutation analysis to identify the site of interaction of novobiocin with Hsp90, and we demonstrate that the novobiocin-binding site resides in the carboxyl terminus of the chaperone.	Novobiocin	95-105	heat shock protein 90 alpha family class A member 1	Homo sapiens	111-116
10945979-6	2000	Surprisingly, this motif also recognizes ATP, and ATP and novobiocin efficiently compete with each other for binding to this region of Hsp90.	Novobiocin	58-68	heat shock protein 90 alpha family class A member 1	Homo sapiens	135-140
10945979-7	2000	Novobiocin interferes with association of the co-chaperones Hsc70 and p23 with Hsp90.	Novobiocin	0-10	heat shock protein family A (Hsp70) member 8	Homo sapiens	60-65
10945979-7	2000	Novobiocin interferes with association of the co-chaperones Hsc70 and p23 with Hsp90.	Novobiocin	0-10	prostaglandin E synthase 3	Homo sapiens	70-73
10945979-7	2000	Novobiocin interferes with association of the co-chaperones Hsc70 and p23 with Hsp90.	Novobiocin	0-10	heat shock protein 90 alpha family class A member 1	Homo sapiens	79-84
10945979-4	2000	We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-1, and p185(ErbB2).	Novobiocin	51-61	heat shock protein 90 alpha family class A member 1	Homo sapiens	82-87
10945979-4	2000	We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-1, and p185(ErbB2).	Novobiocin	51-61	heat shock protein 90 alpha family class A member 1	Homo sapiens	220-225
10945979-4	2000	We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-1, and p185(ErbB2).	Novobiocin	51-61	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	261-266
10945979-4	2000	We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-1, and p185(ErbB2).	Novobiocin	51-61	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	272-276
10945979-4	2000	We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-1, and p185(ErbB2).	Novobiocin	51-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	277-282
10831857-9	2000	Eleven (48%) of the novobiocin resistant CNS were resistant to erythromycin and all these isolates contained the ermA gene.	Novobiocin	20-30	rRNA methylase Erm(A)	Staphylococcus aureus	113-117
11038146-1	2000	PURPOSE: The coumarin antibiotic novobiocin potentiates the activity of etoposide (VP-16) in vitro by increasing intracellular accumulation of VP-16.	Novobiocin	33-43	host cell factor C1	Homo sapiens	83-88
11038146-1	2000	PURPOSE: The coumarin antibiotic novobiocin potentiates the activity of etoposide (VP-16) in vitro by increasing intracellular accumulation of VP-16.	Novobiocin	33-43	host cell factor C1	Homo sapiens	143-148
11038146-3	2000	In a recent study, we found that novobiocin augmented VP-16 accumulation ex vivo in 16 of 24 fresh tumor samples at concentrations that could be achieved in vivo.	Novobiocin	33-43	host cell factor C1	Homo sapiens	54-59
11038146-19	2000	Plasma concentrations of novobiocin equivalent to the levels required to modulate VP-16 in vitro are readily achievable for total but not unbound free drug.	Novobiocin	25-35	host cell factor C1	Homo sapiens	82-87
10901300-0	2000	Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells.	Novobiocin	0-10	host cell factor C1	Homo sapiens	19-24
10901300-0	2000	Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells.	Novobiocin	0-10	ATP binding cassette subfamily C member 1	Homo sapiens	42-45
10901300-1	2000	We have previously reported that novobiocin potentiates the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26) in a number of experimental tumor cell lines by inhibition of the efflux of the epipodophyllotoxins by an ATP-requiring transporter.	Novobiocin	33-43	host cell factor C1	Homo sapiens	93-98
10901300-2	2000	In leukemia cells from 12/19 patients and in ovarian carcinoma cells from 2/4 patients, novobiocin, in a concentration range of 150-1000 microM, increased the intracellular accumulation of VP-16 by 30-250% by inhibiting its efflux.	Novobiocin	88-98	host cell factor C1	Homo sapiens	189-194
10901300-4	2000	Previous findings from our laboratory have provided evidence that the membrane transporter for VP-16 which is inhibited by novobiocin is distinct from the P-glycoprotein.	Novobiocin	123-133	host cell factor C1	Homo sapiens	95-100
10901300-5	2000	The expression of MRP, measured by immunoblotting, was variable in novobiocin-responsive and non-responsive leukemia cells, indicating that no direct relationship existed between the modulatory activity of novobiocin on the transport of VP-16 and the expression of the MRP gene.	Novobiocin	67-77	ATP binding cassette subfamily C member 1	Homo sapiens	18-21
10901300-6	2000	The findings indicate that the novobiocin-sensitive VP-16 transporter is (i) present in high frequency in leukemia and ovarian carcinoma cells, and (ii) probably not the P-glycoprotein or MRP.	Novobiocin	31-41	host cell factor C1	Homo sapiens	52-57
10194666-0	1999	Enhancement of the activity of novobiocin against Escherichia coli by lactoferrin.	Novobiocin	31-41	lactotransferrin	Bos taurus	70-81
10655441-10	2000	Furthermore, novobiocin reduced Raf-1 levels in the spleens of mice treated with the drug.	Novobiocin	13-23	v-raf-leukemia viral oncogene 1	Mus musculus	32-37
10655441-12	2000	Novobiocin"s unique interaction with Hsp90 identifies an additional site on this protein amenable to pharmacologic interference with small molecules.	Novobiocin	0-10	heat shock protein, 2	Mus musculus	37-42
10692168-8	2000	In addition, removal of the known gene silencer H-NS by a mutation in its structural gene hns increased the synthesis of VirF at low temperature and thus induced a virulent phenotype at 30 degrees C. Conversely, decreased expression of VirF at 37 degrees C induced by the addition of novobiocin, a known inhibitor of gyrase, led to an avirulent phenotype.	Novobiocin	284-294	VirF	Shigella flexneri	236-240
11216669-0	2000	Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16).	Novobiocin	30-40	host cell factor C1	Homo sapiens	97-102
11216669-1	2000	We have previously reported that the antibiotic novobiocin enhanced the toxicity of the anticancer agent etoposide (VP-16) to several drug-sensitive and -resistant tumor cell lines.	Novobiocin	48-58	host cell factor C1	Homo sapiens	116-121
11216669-2	2000	The increase in VP-16 cytotoxicity produced by novobiocin was not due to the combined effects of these agents on topoisomerase II, but to inhibition by novobiocin of VP-16 efflux, which in turn led to increased accumulation of VP-16 and increased formation of potentially lethal VP-16-stabilized topoisomerase II-DNA covalent complexes.	Novobiocin	47-57	host cell factor C1	Homo sapiens	16-21
11216669-2	2000	The increase in VP-16 cytotoxicity produced by novobiocin was not due to the combined effects of these agents on topoisomerase II, but to inhibition by novobiocin of VP-16 efflux, which in turn led to increased accumulation of VP-16 and increased formation of potentially lethal VP-16-stabilized topoisomerase II-DNA covalent complexes.	Novobiocin	152-162	host cell factor C1	Homo sapiens	16-21
11216669-2	2000	The increase in VP-16 cytotoxicity produced by novobiocin was not due to the combined effects of these agents on topoisomerase II, but to inhibition by novobiocin of VP-16 efflux, which in turn led to increased accumulation of VP-16 and increased formation of potentially lethal VP-16-stabilized topoisomerase II-DNA covalent complexes.	Novobiocin	152-162	host cell factor C1	Homo sapiens	166-171
11216669-2	2000	The increase in VP-16 cytotoxicity produced by novobiocin was not due to the combined effects of these agents on topoisomerase II, but to inhibition by novobiocin of VP-16 efflux, which in turn led to increased accumulation of VP-16 and increased formation of potentially lethal VP-16-stabilized topoisomerase II-DNA covalent complexes.	Novobiocin	152-162	host cell factor C1	Homo sapiens	166-171
11216669-2	2000	The increase in VP-16 cytotoxicity produced by novobiocin was not due to the combined effects of these agents on topoisomerase II, but to inhibition by novobiocin of VP-16 efflux, which in turn led to increased accumulation of VP-16 and increased formation of potentially lethal VP-16-stabilized topoisomerase II-DNA covalent complexes.	Novobiocin	152-162	host cell factor C1	Homo sapiens	166-171
11216669-3	2000	We have now identified novobiocin analogs that are essentially equivalent to novobiocin as inhibitors of the activity of topoisomerase II, but that are more potent than novobiocin (a) as modulators of the cytotoxicity of VP-16 to WEHI-3B leukemia and A549 lung carcinoma cells and (b) in increasing VP-16 accumulation in these cell lines.	Novobiocin	23-33	host cell factor C1	Homo sapiens	221-226
11216669-3	2000	We have now identified novobiocin analogs that are essentially equivalent to novobiocin as inhibitors of the activity of topoisomerase II, but that are more potent than novobiocin (a) as modulators of the cytotoxicity of VP-16 to WEHI-3B leukemia and A549 lung carcinoma cells and (b) in increasing VP-16 accumulation in these cell lines.	Novobiocin	23-33	host cell factor C1	Homo sapiens	299-304
11216669-4	2000	Thus, removal of the sugar moiety of novobiocin to form novobiocic acid enhanced the potency of the antibiotic as a modulator of VP-16, whereas the substituted coumarin ring alone (U-7587) was devoid of VP-16 modulatory activity.	Novobiocin	37-47	host cell factor C1	Homo sapiens	129-134
11216669-5	2000	Modifications of the side chain of novobiocin significantly influenced modulatory activity, with cyclonovobiocic acid, which was formed from novobiocic acid by acid-catalyzed cycloaddition, being the most active in enhancing the cytotoxicity of VP-16.	Novobiocin	35-45	host cell factor C1	Homo sapiens	245-250
10655441-6	2000	Effects of the coumarin antibiotics novobiocin, chlorobiocin, and coumermycin A1 on several proteins interacting with Hsp90 were assessed in vitro and in vivo.	Novobiocin	36-46	heat shock protein, 2	Mus musculus	118-123
10655441-7	2000	RESULTS: Hsp90 binding to immobilized novobiocin was competed by soluble coumarins and ATP but not by geldanamycin or radicicol.	Novobiocin	38-48	heat shock protein, 2	Mus musculus	9-14
10655441-8	2000	A carboxy-terminal Hsp90 fragment bound immobilized novobiocin but not immobilized geldanamycin, while a geldanamycin-binding amino-terminal fragment did not bind novobiocin.	Novobiocin	52-62	heat shock protein, 2	Mus musculus	19-24
10455234-3	1999	Characterization of one of these mutants, mds1, revealed that it was sensitive not only to novobiocin but also to a wide range of drugs.	Novobiocin	91-101	serine/threonine protein kinase RIM11	Saccharomyces cerevisiae S288C	42-46
10194666-4	1999	When the concentration was increased to 3.0 mg/ml of lactoferrin, novobiocin was bactericidal at 1/64x MIC.	Novobiocin	66-76	lactotransferrin	Bos taurus	53-64
10194666-7	1999	When these strains were also treated with lactoferrin at 3.0 mg/ml, there was a bacteriostatic effect at novobiocin concentrations of 1/8 and 1/16x MIC for strains 6789 and 6800.	Novobiocin	105-115	lactotransferrin	Bos taurus	42-53
9687383-1	1998	We show that the coumeromycin antibiotic novobiocin, a potent inhibitor of ADP ribosylation, prevents lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-10 secretion in human peripheral blood mononuclear cells.	Novobiocin	41-51	tumor necrosis factor	Homo sapiens	135-162
9810637-0	1998	Novobiocin inhibits both UDP-glucuronosyltransferase and cytochrome P450-mediated enzyme activities in pig liver microsomes.	Novobiocin	0-10	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	57-72
9810637-7	1998	These results suggest that novobiocin inhibits not only UDPGTs, but also cytochrome P450 (CYP) enzyme activities, probably those belonging to the CYP3A subfamily.	Novobiocin	27-37	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	73-88
9810637-7	1998	These results suggest that novobiocin inhibits not only UDPGTs, but also cytochrome P450 (CYP) enzyme activities, probably those belonging to the CYP3A subfamily.	Novobiocin	27-37	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	90-93
9687383-1	1998	We show that the coumeromycin antibiotic novobiocin, a potent inhibitor of ADP ribosylation, prevents lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-10 secretion in human peripheral blood mononuclear cells.	Novobiocin	41-51	tumor necrosis factor	Homo sapiens	164-173
9687383-1	1998	We show that the coumeromycin antibiotic novobiocin, a potent inhibitor of ADP ribosylation, prevents lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-10 secretion in human peripheral blood mononuclear cells.	Novobiocin	41-51	interleukin 1 alpha	Homo sapiens	176-189
9687383-1	1998	We show that the coumeromycin antibiotic novobiocin, a potent inhibitor of ADP ribosylation, prevents lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-10 secretion in human peripheral blood mononuclear cells.	Novobiocin	41-51	interleukin 1 alpha	Homo sapiens	191-195
9687383-1	1998	We show that the coumeromycin antibiotic novobiocin, a potent inhibitor of ADP ribosylation, prevents lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-10 secretion in human peripheral blood mononuclear cells.	Novobiocin	41-51	interleukin 6	Homo sapiens	198-202
9687383-1	1998	We show that the coumeromycin antibiotic novobiocin, a potent inhibitor of ADP ribosylation, prevents lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-10 secretion in human peripheral blood mononuclear cells.	Novobiocin	41-51	interleukin 10	Homo sapiens	208-213
9687383-3	1998	We found that novobiocin prevents TNF-alpha production by inhibiting translation of the TNF-alpha mRNA.	Novobiocin	14-24	tumor necrosis factor	Homo sapiens	34-43
9687383-3	1998	We found that novobiocin prevents TNF-alpha production by inhibiting translation of the TNF-alpha mRNA.	Novobiocin	14-24	tumor necrosis factor	Homo sapiens	88-97
9687383-5	1998	Novobiocin causes downregulation of the surface molecules on monocytes, among which CD14 was the most affected.	Novobiocin	0-10	CD14 molecule	Homo sapiens	84-88
9367520-10	1997	Mono-ADP-ribosylation of Gsalpha resulted in an inhibition of the T-tubular adenylate cyclase activity as proven by the suppression of this inhibition using novobiocin as a specific inhibitor of mADP-RT.	Novobiocin	157-167	ADP-ribosyltransferase 1	Mus musculus	195-202
9683467-7	1998	Furthermore, the UV sensitivity of hup mutants cannot be suppressed by overexpression of wild-type or mutant gyrB, which confers novobiocin resistance, or by different concentrations of a gyrase inhibitor that can increase or decrease the supercoiling of chromosomal DNA.	Novobiocin	129-139	DNA-binding protein HU	Escherichia coli	35-38
9445199-1	1998	BACKGROUND: The aim of this study was to determine the efficacy of novobiocin and rifampin as oral antibiotic prophylaxis for the prevention of catheter-related infection in melanoma patients treated with interleukin-2 (IL-2) plus interferon-alpha and chemotherapy (biochemotherapy).	Novobiocin	67-77	interleukin 2	Homo sapiens	205-218
9445199-1	1998	BACKGROUND: The aim of this study was to determine the efficacy of novobiocin and rifampin as oral antibiotic prophylaxis for the prevention of catheter-related infection in melanoma patients treated with interleukin-2 (IL-2) plus interferon-alpha and chemotherapy (biochemotherapy).	Novobiocin	67-77	interleukin 2	Homo sapiens	220-224
9569630-0	1998	Effects of temperature and novobiocin on the expression of calf prochymosin gene and on plasmid copy number in recombinant Escherichia coli.	Novobiocin	27-37	chymosin	Bos taurus	64-75
9236294-3	1997	Screening of LPS mutants was performed with colony dot and sensitivity to novobiocin.	Novobiocin	74-84	toll-like receptor 4	Mus musculus	13-16
7521751-5	1993	In HUVE, the topoisomerase II selective inhibitors novobiocin, nalidixic acid, and etoposide prevented cytokine-induced VCAM-1 surface expression, but not E-selectin or ICAM-1 surface expression.	Novobiocin	51-61	vascular cell adhesion molecule 1	Homo sapiens	120-126
9149974-7	1997	Penicillin plus novobiocin also demonstrated excellent activity against strains of S. aureus that were both positive and negative for beta-lactamase.	Novobiocin	16-26	beta-lactamase	Staphylococcus aureus	134-148
8311468-4	1994	The automodification was inhibited by the acceptor, arginine or agmatine, and an inhibitor of arginine-specific ADP-ribosyltransferase, novobiocin.	Novobiocin	136-146	ADP-ribosyltransferase 1 like 3	Gallus gallus	112-134
9217112-0	1997	Effect of temperature and agitation on enrichment of Escherichia coli O157:H7 in ground beef using modified EC broth with novobiocin.	Novobiocin	122-132	chemokine (C-C motif) ligand 28	Mus musculus	108-110
7803497-0	1994	Novobiocin activates the mating response in yeast through the alpha-pheromone receptor, Ste2p.	Novobiocin	0-10	alpha-factor pheromone receptor STE2	Saccharomyces cerevisiae S288C	88-93
7803497-6	1994	Thus, novobiocin is a functional agonist of Ste2p, and may identify a potentially useful interaction between coumarin drugs and the family of G-protein-coupled receptors.	Novobiocin	6-16	alpha-factor pheromone receptor STE2	Saccharomyces cerevisiae S288C	44-49
8106148-0	1993	Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.	Novobiocin	106-116	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
8106148-1	1993	Previous reports from this laboratory have demonstrated that novobiocin produces supraadditive cytotoxicity and increases the formation of drug-stabilized topoisomerase II-DNA covalent complexes in WEHI-3B myelomonocytic leukemia and A549 lung carcinoma cells when combined with etoposide (VP-16).	Novobiocin	61-71	host cell factor C1	Homo sapiens	290-295
8106148-2	1993	Inhibition of the efflux of VP-16 by novobiocin is responsible for the increase in VP-16 accumulation, which in turn leads to increased formation of VP-16-stabilized topoisomerase II-DNA covalent complexes and increased cytotoxicity.	Novobiocin	37-47	host cell factor C1	Homo sapiens	28-33
8106148-2	1993	Inhibition of the efflux of VP-16 by novobiocin is responsible for the increase in VP-16 accumulation, which in turn leads to increased formation of VP-16-stabilized topoisomerase II-DNA covalent complexes and increased cytotoxicity.	Novobiocin	37-47	host cell factor C1	Homo sapiens	83-88
8106148-2	1993	Inhibition of the efflux of VP-16 by novobiocin is responsible for the increase in VP-16 accumulation, which in turn leads to increased formation of VP-16-stabilized topoisomerase II-DNA covalent complexes and increased cytotoxicity.	Novobiocin	37-47	host cell factor C1	Homo sapiens	83-88
8106148-3	1993	We now report that novobiocin synergistically enhanced the sensitivity of the multidrug resistant variants, WEHI-3B/NOVO and A549(VP)28, to VP-16, causing almost complete reversal of the resistance to the epipodophyllotoxin.	Novobiocin	19-29	host cell factor C1	Homo sapiens	140-145
8106148-5	1993	The effects of novobiocin in these resistant sublines are mediated through the intracellular accumulation of VP-16, resulting in an increase in the formation of lethal VP-16-induced topoisomerase II-DNA covalent complexes.	Novobiocin	15-25	host cell factor C1	Homo sapiens	109-114
8106148-5	1993	The effects of novobiocin in these resistant sublines are mediated through the intracellular accumulation of VP-16, resulting in an increase in the formation of lethal VP-16-induced topoisomerase II-DNA covalent complexes.	Novobiocin	15-25	host cell factor C1	Homo sapiens	168-173
8106148-6	1993	In the P-glycoprotein expressing multidrug resistant HCT116(VM)34 colon carcinoma and L1210/VMDRC0.06 leukemia cell lines, the latter being transfected with the human mdr-1 gene, novobiocin did not potentiate the cytotoxic activity of VP-16 nor increase the intracellular accumulation of VP-16 and the formation of covalent complexes, whereas their normal counterparts were sensitive to the potentiating activity of novobiocin when used in combination with VP-16.	Novobiocin	179-189	ATP binding cassette subfamily B member 1	Homo sapiens	7-21
8106148-7	1993	These results indicate that the action of novobiocin on the intracellular transport of VP-16 is not directed at the level of the P-glycoprotein, but that the action of novobiocin is antagonized by the presence of the P-glycoprotein.	Novobiocin	42-52	host cell factor C1	Homo sapiens	87-92
8106148-7	1993	These results indicate that the action of novobiocin on the intracellular transport of VP-16 is not directed at the level of the P-glycoprotein, but that the action of novobiocin is antagonized by the presence of the P-glycoprotein.	Novobiocin	42-52	ATP binding cassette subfamily B member 1	Homo sapiens	217-231
8106148-7	1993	These results indicate that the action of novobiocin on the intracellular transport of VP-16 is not directed at the level of the P-glycoprotein, but that the action of novobiocin is antagonized by the presence of the P-glycoprotein.	Novobiocin	168-178	host cell factor C1	Homo sapiens	87-92
8106148-7	1993	These results indicate that the action of novobiocin on the intracellular transport of VP-16 is not directed at the level of the P-glycoprotein, but that the action of novobiocin is antagonized by the presence of the P-glycoprotein.	Novobiocin	168-178	ATP binding cassette subfamily B member 1	Homo sapiens	217-231
8106148-8	1993	Since novobiocin is a clinically available antibiotic, has numerous structural analogues available for comparative studies, and has a relatively low toxicity profile, this drug, as well as structurally related agents, would appear to have significant clinical potential in combination with an epipodophyllotoxin for the treatment of non-P-glycoprotein expressing multidrug resistant tumors.	Novobiocin	6-16	ATP binding cassette subfamily B member 1	Homo sapiens	337-351
7521751-6	1993	Similarly, novobiocin and nalidixic acid reduced the accumulation of VCAM-1 mRNA in response to tumor necrosis factor-alpha treatment of HUVE.	Novobiocin	11-21	vascular cell adhesion molecule 1	Homo sapiens	69-75
7521751-6	1993	Similarly, novobiocin and nalidixic acid reduced the accumulation of VCAM-1 mRNA in response to tumor necrosis factor-alpha treatment of HUVE.	Novobiocin	11-21	tumor necrosis factor	Homo sapiens	96-123
1846146-0	1991	Mutations in DNA gyrase result in novobiocin resistance in halophilic archaebacteria.	Novobiocin	34-44	DNA topoisomerase II alpha	Homo sapiens	13-23
1330653-6	1992	Differentiation induction and the G2/M arrest evoked by VP-16, VM-26, and mAMSA were, however, reduced in the presence of novobiocin.	Novobiocin	122-132	host cell factor C1	Homo sapiens	56-61
1330339-3	1992	The resulting ideas were tested through the rational design and synthesis of original phospholipid structures linked to novobiocin subsequently used in the production of two-dimensional crystals of DNA gyrase (B subunit), a prokaryotic type II DNA topoisomerase.	Novobiocin	120-130	DNA topoisomerase II alpha	Homo sapiens	198-208
1379327-0	1992	Modulation by novobiocin of sister-chromatid exchanges induced by tumor necrosis factor in human lymphocytes.	Novobiocin	14-24	tumor necrosis factor	Homo sapiens	66-87
1379327-1	1992	The effect of the antibiotic novobiocin on human recombinant tumor necrosis factor (TNF)-induced sister-chromatid exchanges (SCEs) were examined in human peripheral blood lymphocytes.	Novobiocin	29-39	tumor necrosis factor	Homo sapiens	61-82
1379327-1	1992	The effect of the antibiotic novobiocin on human recombinant tumor necrosis factor (TNF)-induced sister-chromatid exchanges (SCEs) were examined in human peripheral blood lymphocytes.	Novobiocin	29-39	tumor necrosis factor	Homo sapiens	84-87
1377186-0	1992	Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).	Novobiocin	16-26	host cell factor C1	Homo sapiens	67-72
1377186-1	1992	The coumermycin antibiotic novobiocin, which interacts with the nuclear enzyme topoisomerase II, produced supra-additive toxicity to WEHI-3B D+ leukemia cells at clinically achievable concentrations, when combined with teniposide (VM-26) or etoposide (VP-16).	Novobiocin	27-37	host cell factor C1	Homo sapiens	252-257
1377186-3	1992	Novobiocin also produced supra-additive toxicity to A549 human lung carcinoma cells when combined with VM-26 or VP-16.	Novobiocin	0-10	host cell factor C1	Homo sapiens	112-117
1377186-9	1992	Our findings suggest that therapeutic levels of novobiocin may be capable of enhancing the clinical activities of VP-16 and VM-26.	Novobiocin	48-58	host cell factor C1	Homo sapiens	114-119
1356096-0	1992	Inhibition of T-cell mediated cytotoxicity by Novobiocin suggests multiple pathways for both CD4+ and CD8+ cytotoxic T cells.	Novobiocin	46-56	CD4 molecule	Homo sapiens	93-96
1356096-0	1992	Inhibition of T-cell mediated cytotoxicity by Novobiocin suggests multiple pathways for both CD4+ and CD8+ cytotoxic T cells.	Novobiocin	46-56	CD8a molecule	Homo sapiens	102-105
1356096-2	1992	When effector cells were class I major histocompatibility complex (MHC)-specific CD8+ cytotoxic T cells (Tc), Novobiocin caused a biphasic pattern of inhibition and the two components of the inhibition could be separated based on Ca2+ requirement.	Novobiocin	110-120	CD8a molecule	Homo sapiens	81-84
21584513-4	1992	However, CAT activity could not be significantly induced when treated with an ATP-antagoist, novobiocin.	Novobiocin	93-103	catalase	Homo sapiens	9-12
2170526-7	1990	In contrast, the topoisomerase II inhibitors novobiocin and coumermycin, which bind to the enzyme ATPase site, protect L929 cells from TNF cytotoxicity but enhance TNF cytotoxicity in ME-180 cells.	Novobiocin	45-55	tumor necrosis factor	Mus musculus	135-138
2170526-7	1990	In contrast, the topoisomerase II inhibitors novobiocin and coumermycin, which bind to the enzyme ATPase site, protect L929 cells from TNF cytotoxicity but enhance TNF cytotoxicity in ME-180 cells.	Novobiocin	45-55	tumor necrosis factor	Mus musculus	164-167
35550413-6	2022	Activities of major efflux transporters, MDR1, MRP1, and BCRP, were assessed using their respective blockers, verapamil, probenecid, and novobiocin.	Novobiocin	137-147	BCR pseudogene 1	Homo sapiens	57-61
35625344-7	2022	MsbA has previously been identified as a multidrug transporter in E. coli, and as P. aeruginosa MsbA presented 76% identity with E. coli MsbA, it is possible that novobiocin efflux involves this ABC transporter, accounting for about 30% of the bacterium resistance to this antibiotic.	Novobiocin	163-173	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	195-198
33769048-3	2021	In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin.	Novobiocin	145-155	GABA type A receptor associated protein like 1	Homo sapiens	64-68
33769048-3	2021	In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin.	Novobiocin	145-155	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	86-90
33769048-3	2021	In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin.	Novobiocin	145-155	microtubule associated protein 1 light chain 3 beta	Homo sapiens	95-99
34977827-10	2022	Also, isolate PS2 showed resistance to erythromycin, ciprofloxacin, methicillin, novobiocin and penicillin.	Novobiocin	81-91	taste 2 receptor member 64 pseudogene	Homo sapiens	14-17
34559588-8	2022	The combined usage of novobiocin and the low-molecular-weight polymers reduced the minimum inhibitory concentration, which was less than 0.0625 mug/mL against E. coli.	Novobiocin	22-32	thrombopoietin	Mus musculus	148-150